<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Establishment Labs Holdings Inc. Citi's 2025 Unplugged Medtech and Life Sciences Access Day  Feb 27, 2025<br><br>Speaker 1: So we saw a lot of announcements, at the January, and not just the fourth quarter preannouncement, the 2025 guide, but also, a management change. And I thought a good place to start today's conversation would be, if you could sort of address some of those changes,<br>how you're thinking about them. And, Pete, if there's anything you'd like to sort of jump in now, assuming you're the permanent CEO, you can correct me. Speaker 1: And, what you might do in that position? Speaker 2: Okay. Alright.</td><td>**Establishment Labs Holdings Inc. ì”¨í‹° 2025 ì–¸í”ŒëŸ¬ê·¸ë“œ ë©”ë“œí…Œí¬ ë° ìƒëª…ê³¼í•™ ì•¡ì„¸ìŠ¤ ë°ì´**  <br>**2025ë…„ 2ì›” 27ì¼**<br><br>**ë°œí‘œì 1:** 1ì›”ì— ë§ì€ ë°œí‘œë“¤ì„ ë³´ì•˜ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì‚¬ì „ ë°œí‘œë¿ë§Œ ì•„ë‹ˆë¼ 2025ë…„ ê°€ì´ë˜ìŠ¤, ê·¸ë¦¬ê³  ê²½ì˜ì§„ ë³€ê²½ë„ ìˆì—ˆì£ . ì˜¤ëŠ˜ ëŒ€í™”ë¥¼ ì‹œì‘í•˜ê¸°ì— ì¢‹ì€ ì§€ì ì€ ê·¸ëŸ¬í•œ ë³€í™”ë“¤ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œëŠ” ê²ƒì¼ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í”¼íŠ¸, ë§Œì•½ ë‹¹ì‹ ì´ ì •ì‹ CEOë¼ê³  ê°€ì •í•œë‹¤ë©´ - í‹€ë ¸ë‹¤ë©´ ì •ì •í•´ ì£¼ì„¸ìš” - ê·¸ ìë¦¬ì—ì„œ ë¬´ì—‡ì„ í•˜ì‹¤ ìƒê°ì¸ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?<br><br>**ë°œí‘œì 2:** ë„¤, ì•Œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So, you know, first off, in terms of when you look at our strategy and our priorities, I don't think externally you're gonna see a fundamental change. You know, I think when you look at this company, we have the best products in the industry. Certainly, from a safety profile, we have the the best innovation, and we have tremendous growth opportunities when you look at our priorities. Speaker 2: When you talk about, you know, scaling in The US, when you continue to expand the minimally invasive platform, the innovation that we have. So those priorities are not gonna change.</td><td>ë¨¼ì € ì €í¬ì˜ ì „ëµê³¼ ìš°ì„ ìˆœìœ„ë¥¼ ì‚´í´ë³´ì‹œë©´, ì™¸ë¶€ì ìœ¼ë¡œëŠ” ê·¼ë³¸ì ì¸ ë³€í™”ë¥¼ ë³´ì‹œì§€ ëª»í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ íšŒì‚¬ë¥¼ ë³´ì‹œë©´, ì €í¬ëŠ” ì—…ê³„ ìµœê³ ì˜ ì œí’ˆì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ ì¸¡ë©´ì—ì„œ ì €í¬ëŠ” ìµœê³ ì˜ í˜ì‹ ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ì €í¬ì˜ ìš°ì„ ìˆœìœ„ë¥¼ ê³ ë ¤í•  ë•Œ ì—„ì²­ë‚œ ì„±ì¥ ê¸°íšŒë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>í™”ì 2: ë¯¸êµ­ì—ì„œì˜ í™•ì¥ì— ëŒ€í•´ ë§ì”€í•˜ì‹œë©´, ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ê³  ì €í¬ê°€ ë³´ìœ í•œ í˜ì‹ ì„ ë°œì „ì‹œì¼œ ë‚˜ê°ˆ ë•Œ, ì´ëŸ¬í•œ ìš°ì„ ìˆœìœ„ë“¤ì€ ë³€í•˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>You know, my focus is really gonna be on ensuring that we deliver and maximize revenue potential of those priorities, and at the same time, delivering on our profitability targets. And a lot of that is is just really gonna be around operational discipline. And, you know, I think as a company over the last twelve to eighteen months, done a lot to to right size the business, you know, strip out a lot of operating expenses. Speaker 2: And and we're gonna continue to look at that. But, you know, I think we're gonna be a little bit more selective and look at ways that we can actually, streamline a lot of the back end<br><br>of the business.</td><td>ì œ ì§‘ì¤‘ ë¶„ì•¼ëŠ” ì •ë§ë¡œ ì´ëŸ¬í•œ ìš°ì„ ìˆœìœ„ë“¤ì˜ ë§¤ì¶œ ì ì¬ë ¥ì„ ì‹¤í˜„í•˜ê³  ê·¹ëŒ€í™”í•˜ëŠ” ë™ì‹œì— ìˆ˜ìµì„± ëª©í‘œë¥¼ ë‹¬ì„±í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ëŒ€ë¶€ë¶„ì€ ìš´ì˜ ê·œìœ¨ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì§€ë‚œ 12ê°œì›”ì—ì„œ 18ê°œì›” ë™ì•ˆ íšŒì‚¬ë¡œì„œ ì‚¬ì—… ê·œëª¨ë¥¼ ì ì •í™”í•˜ê³  ë§ì€ ìš´ì˜ë¹„ìš©ì„ ì œê±°í•˜ëŠ” ë“± ë§ì€ ì¼ì„ í•´ì™”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>í™”ì 2: ê·¸ë¦¬ê³  ì €í¬ëŠ” ì´ë¥¼ ê³„ì† ê²€í† í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” ì¢€ ë” ì„ ë³„ì ìœ¼ë¡œ ì ‘ê·¼í•˜ì—¬ ì‚¬ì—…ì˜ ë°±ì—”ë“œ ë¶€ë¶„ì„ ì‹¤ì œë¡œ ê°„ì†Œí™”í•  ìˆ˜ ìˆëŠ” ë°©ë²•ë“¤ì„ ëª¨ìƒ‰í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And I think, you know, the the closure of B fifteen is a great example of that. So we'll continue to look at different opportunities in in that area. But it's really around instilling the operational financial targets. Speaker 2: But from a strategic standpoint, I don't think you're gonna see a lot of changes. Speaker 3: Yeah. And I'd like like to add to that that, you should also think about, you know, the, you know, the evolution of Establishment Labs over the last few years, you know, and through that angle, what's coming next? And what's coming next is this big push by the board to make sure that we become a profitable company in the very near future.</td><td>ê·¸ë¦¬ê³  B15ì˜ íì‡„ê°€ ê·¸ì— ëŒ€í•œ ì¢‹ì€ ì‚¬ë¡€ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” í•´ë‹¹ ì˜ì—­ì—ì„œ ë‹¤ì–‘í•œ ê¸°íšŒë“¤ì„ ê³„ì† ê²€í† í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ì‹¤ì œë¡œ ìš´ì˜ìƒ ì¬ë¬´ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ëŠ” ê²ƒì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 2: í•˜ì§€ë§Œ ì „ëµì  ê´€ì ì—ì„œëŠ” í° ë³€í™”ë¥¼ ë³´ì‹œì§€ëŠ” ëª»í•  ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë„¤. ê·¸ë¦¬ê³  ë§ë¶™ì´ê³  ì‹¶ì€ ê²ƒì€, ì§€ë‚œ ëª‡ ë…„ê°„ Establishment Labsì˜ ë°œì „ ê³¼ì •ì„ ìƒê°í•´ë³´ì‹œê³ , ê·¸ëŸ° ê´€ì ì—ì„œ ë‹¤ìŒì— ë¬´ì—‡ì´ ì˜¬ì§€ ìƒê°í•´ë³´ì…”ì•¼ í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ìŒì— ì˜¬ ê²ƒì€ ê°€ê¹Œìš´ ë¯¸ë˜ì— ì €í¬ê°€ ìˆ˜ìµì„± ìˆëŠ” íšŒì‚¬ê°€ ë˜ë„ë¡ í•˜ê² ë‹¤ëŠ” ì´ì‚¬íšŒì˜ ê°•ë ¥í•œ ì¶”ì§„ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So having Pete, who's got like amazing experience scaling companies globally, managing profitable business is a very important thing while I continue to support the company in the entire innovation space. Speaker 1: Sounds good. Before we get into some more specific things, there's a lot coming out of Washington, and we're looking at tariffs for Medicaid cuts, changes at the FDA, NIH funding changes. Can you address any or all that may or may not impact your business? Speaker 3: I think we've been looking at all the risk factors related to, you know, the current state of affairs, let's call it.</td><td>ë”°ë¼ì„œ ì „ ì„¸ê³„ì ìœ¼ë¡œ íšŒì‚¬ë¥¼ í™•ì¥í•˜ê³  ìˆ˜ìµì„± ìˆëŠ” ì‚¬ì—…ì„ ê´€ë¦¬í•˜ëŠ” ë° ë›°ì–´ë‚œ ê²½í—˜ì„ ê°€ì§„ Peteë¥¼ ì˜ì…í•œ ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•œ ì¼ì…ë‹ˆë‹¤. ì €ëŠ” ê³„ì†í•´ì„œ ì „ì²´ í˜ì‹  ì˜ì—­ì—ì„œ íšŒì‚¬ë¥¼ ì§€ì›í•  ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì¢‹ìŠµë‹ˆë‹¤. ì¢€ ë” êµ¬ì²´ì ì¸ ì‚¬ì•ˆë“¤ì„ ë‹¤ë£¨ê¸° ì „ì—, ì›Œì‹±í„´ì—ì„œ ë§ì€ ë³€í™”ê°€ ë‚˜ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ê´€ì„¸, ë©”ë””ì¼€ì´ë“œ ì‚­ê°, FDA ë³€í™”, NIH ìê¸ˆ ì§€ì› ë³€í™” ë“±ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²ƒë“¤ì´ ê·€í•˜ì˜ ì‚¬ì—…ì— ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ë„ ìˆê³  ê·¸ë ‡ì§€ ì•Šì„ ìˆ˜ë„ ìˆëŠ”ë°, ì´ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?<br><br>ë°œí‘œì 3: í˜„ì¬ ìƒí™©ê³¼ ê´€ë ¨ëœ ëª¨ë“  ìœ„í—˜ ìš”ì†Œë“¤ì„ ì‚´í´ë³´ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And, one one of the most important things is that we were able to get our PMA approved before all of that. So I think the uncertainty is more around, you know, the specifics of how that transition is going to take place. But I think when it comes to, you know, the PMA supplements that we are already undergoing, we have seen no change in the cadence and the frequency of our communications with the FDA. So I think on that side, the supplements that we are doing are fairly simple, including the one for breast reconstruction that we should have three year data this summer.</td><td>ê·¸ë¦¬ê³  ê°€ì¥ ì¤‘ìš”í•œ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ê·¸ ëª¨ë“  ì¼ì´ ì¼ì–´ë‚˜ê¸° ì „ì— PMA ìŠ¹ì¸ì„ ë°›ì„ ìˆ˜ ìˆì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë¶ˆí™•ì‹¤ì„±ì€ ê·¸ ì „í™˜ì´ ì–´ë–»ê²Œ êµ¬ì²´ì ìœ¼ë¡œ ì´ë£¨ì–´ì§ˆì§€ì— ëŒ€í•œ ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ë¯¸ ì§„í–‰ ì¤‘ì¸ PMA ë³´ì™„ì„œë¥˜ë“¤ì˜ ê²½ìš°, FDAì™€ì˜ ì†Œí†µ ë¹ˆë„ë‚˜ ì†ë„ì—ëŠ” ë³€í™”ê°€ ì—†ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ ì¸¡ë©´ì—ì„œ ë³´ë©´, ìš°ë¦¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” ë³´ì™„ì„œë¥˜ë“¤ì€ ìƒë‹¹íˆ ê°„ë‹¨í•œ í¸ì´ë©°, ì—¬ê¸°ì—ëŠ” ì˜¬ ì—¬ë¦„ì— 3ë…„ ë°ì´í„°ë¥¼ í™•ë³´í•  ì˜ˆì •ì¸ ìœ ë°©ì¬ê±´ìˆ  ê´€ë ¨ ë³´ì™„ì„œë¥˜ë„ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: So as we look into the other risk factors like tariffs, you know, I think what the current administration is focused on is on countries that have tariffs on US products and<br><br>making it that a retaliatory strategy to kind of like even the playing field. And when it comes to establishment labs, we manufacture all of our products in Costa Rica. Speaker 1: Mhmm. Speaker 3: Just, you know, there's a big medtech hub in Costa Rica. You know, you see some of the best companies in medtech doing manufacturing in Costa Rica. So I think the important thing is to realize that at this point, there's zero tariffs on US products coming into Costa Rica.</td><td>ë°œí‘œì 3: ê´€ì„¸ì™€ ê°™ì€ ë‹¤ë¥¸ ìœ„í—˜ ìš”ì¸ë“¤ì„ ì‚´í´ë³´ë©´, í˜„ í–‰ì •ë¶€ê°€ ì§‘ì¤‘í•˜ê³  ìˆëŠ” ê²ƒì€ ë¯¸êµ­ ì œí’ˆì— ê´€ì„¸ë¥¼ ë¶€ê³¼í•˜ëŠ” êµ­ê°€ë“¤ì— ëŒ€í•´ <br><br>ê²½ìŸì˜ ì¥ì„ í‰ë“±í•˜ê²Œ ë§Œë“¤ê¸° ìœ„í•œ ì¼ì¢…ì˜ ë³´ë³µ ì „ëµì„ ì·¨í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Establishment Labsì˜ ê²½ìš°, ì €í¬ëŠ” ëª¨ë“  ì œí’ˆì„ ì½”ìŠ¤íƒ€ë¦¬ì¹´ì—ì„œ ì œì¡°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°œí‘œì 1: ë„¤. ë°œí‘œì 3: ì½”ìŠ¤íƒ€ë¦¬ì¹´ì—ëŠ” ëŒ€ê·œëª¨ ì˜ë£Œê¸°ê¸° í—ˆë¸Œê°€ ìˆìŠµë‹ˆë‹¤. ì˜ë£Œê¸°ê¸° ë¶„ì•¼ ìµœê³ ì˜ ê¸°ì—…ë“¤ì´ ì½”ìŠ¤íƒ€ë¦¬ì¹´ì—ì„œ ì œì¡°ë¥¼ í•˜ê³  ìˆëŠ” ê²ƒì„ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì¤‘ìš”í•œ ì ì€ í˜„ì¬ ì½”ìŠ¤íƒ€ë¦¬ì¹´ë¡œ ë“¤ì–´ì˜¤ëŠ” ë¯¸êµ­ ì œí’ˆì— ëŒ€í•´ì„œëŠ” ê´€ì„¸ê°€ ì „í˜€ ì—†ë‹¤ëŠ” ê²ƒì„ ì¸ì‹í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So there's no real reason for the current administration to single out that country for a retaliatory target. I think they're know, they have other bigger targets on their mind. Speaker 1: Fresh off of earnings. Raj, would you like to sort of give us a state of the union of what was reported last night? Speaker 4: Sure. Thank you. Yes. We did report our fourth quarter numbers last night after the market closed. I think generally, we viewed it as a very positive update for us. Speaker 4: Revenue was $44,500,000 It was up a little above 40% from, from the fourth quarter of twenty twenty three.</td><td>ë”°ë¼ì„œ í˜„ í–‰ì •ë¶€ê°€ í•´ë‹¹ êµ­ê°€ë¥¼ ë³´ë³µ ëŒ€ìƒìœ¼ë¡œ íŠ¹ë³„íˆ ì§€ëª©í•  ì‹¤ì§ˆì ì¸ ì´ìœ ëŠ” ì—†ìŠµë‹ˆë‹¤. ê·¸ë“¤ì—ê²ŒëŠ” ë” í° ëª©í‘œë“¤ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì‹¤ì  ë°œí‘œë¥¼ ë§‰ ë§ˆì¹œ ìƒí™©ì—ì„œ, Rajë‹˜, ì–´ì ¯ë°¤ ë°œí‘œëœ ë‚´ìš©ì— ëŒ€í•´ ì „ë°˜ì ì¸ í˜„í™©ì„ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>ë°œí‘œì 4: ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì–´ì ¯ë°¤ ì¥ ë§ˆê° í›„ 4ë¶„ê¸° ì‹¤ì ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ë§¤ìš° ê¸ì •ì ì¸ ì—…ë°ì´íŠ¸ì˜€ë‹¤ê³  í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë§¤ì¶œì€ 4,450ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” 2023ë…„ 4ë¶„ê¸° ëŒ€ë¹„ 40%ë¥¼ ì•½ê°„ ìƒíšŒí•˜ëŠ” ì¦ê°€ìœ¨ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Again, we saw some slowdowns in the market over that period of time, but we're seeing a nice recovery in the business overall there. Importantly, within that revenue number, there was $3,300,000 of sales into The United States for Motiva post approval, which again, given that we it was only for a short period of time in the quarter, it was actually very positive result for us, we think, and we could talk certainly, I'm sure, about some of the business. Gross margins, 68.5%, the strongest we've seen in years for us as a company, frankly.</td><td>ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, í•´ë‹¹ ê¸°ê°„ ë™ì•ˆ ì‹œì¥ì—ì„œ ì¼ë¶€ ë‘”í™”ë¥¼ ë³´ì•˜ì§€ë§Œ, ì „ë°˜ì ìœ¼ë¡œ ì‚¬ì—…ì—ì„œ ì¢‹ì€ íšŒë³µì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€ í•´ë‹¹ ë§¤ì¶œ ìˆ˜ì¹˜ ë‚´ì—ì„œ Motiva ìŠ¹ì¸ í›„ ë¯¸êµ­ìœ¼ë¡œì˜ ë§¤ì¶œì´ 330ë§Œ ë‹¬ëŸ¬ì˜€ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ë¶„ê¸° ì¤‘ ì§§ì€ ê¸°ê°„ ë™ì•ˆë§Œ ì´ë£¨ì–´ì§„ ê²ƒì„ ê³ ë ¤í•  ë•Œ ì‹¤ì œë¡œ ë§¤ìš° ê¸ì •ì ì¸ ê²°ê³¼ì˜€ë‹¤ê³  ìƒê°í•˜ë©°, ë¬¼ë¡  ì‚¬ì—…ì— ëŒ€í•´ ë” ìì„¸íˆ ë…¼ì˜í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµë¥ ì€ 68.5%ë¡œ, ì†”ì§íˆ ë§í•´ì„œ ì €í¬ íšŒì‚¬ê°€ ìˆ˜ë…„ê°„ ë³¸ ê²ƒ ì¤‘ ê°€ì¥ ê°•ë ¥í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And that's being driven, as Pete noted, by closing of one of our three manufacturing facilities, as well as some of the early benefits we're seeing from pricing in The United States. Speaker 4: And so we expect gross margins will continue to improve over time. And then on<br><br>the expenses, I think over the course of 2024, as Pete noted, we have reduced operating expenses dramatically. And so for the full year, our overall operating expenses were down over<br>$12,000,000 and that's despite a period of time where we were standing up a significant operation in The United States. And so we we really did reduce quite a bit internally in terms of our spending.</td><td>ê·¸ë¦¬ê³  ì´ëŠ” Peteê°€ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´ 3ê°œ ì œì¡° ì‹œì„¤ ì¤‘ í•˜ë‚˜ì˜ íì‡„ì™€ ë”ë¶ˆì–´ ë¯¸êµ­ì—ì„œì˜ ê°€ê²© ì±…ì •ìœ¼ë¡œë¶€í„° ì–»ê³  ìˆëŠ” ì´ˆê¸° íš¨ìµë“¤ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ë§¤ì¶œì´ì´ìµë¥ ì´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ì§€ì†ì ìœ¼ë¡œ ê°œì„ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¹„ìš© ì¸¡ë©´ì—ì„œëŠ”, Peteê°€ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´ 2024ë…„ í•œ í•´ ë™ì•ˆ ìš°ë¦¬ëŠ” ìš´ì˜ë¹„ìš©ì„ ê·¹ì ìœ¼ë¡œ ì ˆê°í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ì „ì²´ì ìœ¼ë¡œ ìš°ë¦¬ì˜ ì „ì²´ ìš´ì˜ë¹„ìš©ì€ 1,200ë§Œ ë‹¬ëŸ¬ ì´ìƒ ê°ì†Œí–ˆìœ¼ë©°, ì´ëŠ” ë¯¸êµ­ì—ì„œ ëŒ€ê·œëª¨ ìš´ì˜ì„ êµ¬ì¶•í•˜ë˜ ê¸°ê°„ì´ ìˆì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ë‹¬ì„±í•œ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ë‚´ë¶€ì ìœ¼ë¡œ ì§€ì¶œ ì¸¡ë©´ì—ì„œ ìƒë‹¹í•œ ì ˆê°ì„ ì‹¤ì œë¡œ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And then in terms of the outlook, which we can talk about, we reaffirmed the guidance for for 2025, including, 70 to seven 70 to a hundred and 75,000,000 outside The United States, which is mid single digit growth, which we feel very comfortable about. Speaker 4: And then, 35,000,000 in The US, which we'll talk, I'm sure, about some of the metrics we're seeing there, but we view that as a very achievable target as well. So overall, for us, we viewed it as a very positive update for us on on the fourth quarter of last year. Speaker 1: And one of the things that, I thought was really notable from the call last night of some of the stability that it sounds like you're seeing in those.</td><td>ê·¸ë¦¬ê³  ì „ë§ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ë¶€ë¶„ì€, ì €í¬ê°€ 2025ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ì¬í™•ì¸í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ 7ì²œë§Œì—ì„œ 7ì²œ 5ë°±ë§Œ ê±´ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ë¡œ ì €í¬ê°€ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤.<br><br>í™”ì 4: ê·¸ë¦¬ê³  ë¯¸êµ­ ë‚´ì—ì„œëŠ” 3ì²œ 5ë°±ë§Œ ê±´ì¸ë°, ì €í¬ê°€ ê·¸ê³³ì—ì„œ ë³´ê³  ìˆëŠ” ëª‡ ê°€ì§€ ì§€í‘œë“¤ì— ëŒ€í•´ì„œëŠ” ë¶„ëª…íˆ ë…¼ì˜í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤ë§Œ, ì´ ë˜í•œ ë§¤ìš° ë‹¬ì„± ê°€ëŠ¥í•œ ëª©í‘œë¼ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì „ë°˜ì ìœ¼ë¡œ ì €í¬ì—ê²ŒëŠ” ì‘ë…„ 4ë¶„ê¸°ì— ëŒ€í•œ ë§¤ìš° ê¸ì •ì ì¸ ì—…ë°ì´íŠ¸ì˜€ë‹¤ê³  í‰ê°€í•©ë‹ˆë‹¤.<br><br>í™”ì 1: ê·¸ë¦¬ê³  ì–´ì ¯ë°¤ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ì •ë§ ì£¼ëª©í•  ë§Œí–ˆë˜ ì  ì¤‘ í•˜ë‚˜ëŠ”, í•´ë‹¹ ë¶€ë¬¸ë“¤ì—ì„œ ë³´ê³  ê³„ì‹ ë‹¤ê³  í•˜ëŠ” ì•ˆì •ì„±ì˜ ì¼ë¶€ë¶„ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And and I it's you know, we lump it all as outside The United States, and it's not exactly fair because there are so many countries that you participate in. And so, you know, I not country by country, but if you could give us sort of a highlight reel of what you're seeing in, in. Speaker 4: Certainly. Yes. So, you know, if you think about, really the three regions outside of The United States or North America, Asia Pacific has generally been been pretty good. You know, it feels stable, if not if not, even a bit better. We do have an interesting dynamic in our Chinese market where we're seeing good end market growth there.</td><td>ê·¸ë¦¬ê³  ì €í¬ê°€ ë¯¸êµ­ ì™¸ ì§€ì—­ì„ ëª¨ë‘ í•˜ë‚˜ë¡œ ë¬¶ì–´ì„œ í‘œí˜„í•˜ëŠ”ë°, ì‚¬ì‹¤ ì´ëŠ” ì •í™•í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ê·€í•˜ê°€ ì°¸ì—¬í•˜ê³  ìˆëŠ” êµ­ê°€ê°€ ë§¤ìš° ë§ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ êµ­ê°€ë³„ë¡œëŠ” ì•„ë‹ˆë”ë¼ë„, ê·€í•˜ê°€ ë³´ê³  ê³„ì‹  ìƒí™©ì— ëŒ€í•œ í•˜ì´ë¼ì´íŠ¸ë¥¼ ì œê³µí•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ”ì§€ìš”.<br><br>**í™”ì 4:** ë¬¼ë¡ ì…ë‹ˆë‹¤. ë„¤, ë¯¸êµ­ì´ë‚˜ ë¶ë¯¸ ì™¸ ì§€ì—­ì„ í¬ê²Œ ì„¸ ê°œ ì§€ì—­ìœ¼ë¡œ ë‚˜ëˆ„ì–´ ë³´ë©´, ì•„ì‹œì•„ íƒœí‰ì–‘ ì§€ì—­ì€ ì „ë°˜ì ìœ¼ë¡œ ê½¤ ì–‘í˜¸í•œ ìƒí™©ì…ë‹ˆë‹¤. ì•ˆì •ì ì´ë¼ê³  ëŠê»´ì§€ë©°, ì‹¬ì§€ì–´ ì¡°ê¸ˆ ë” ë‚˜ì•„ì§€ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì¤‘êµ­ ì‹œì¥ì—ì„œëŠ” í¥ë¯¸ë¡œìš´ ì—­í•™ê´€ê³„ë¥¼ ë³´ì´ê³  ìˆëŠ”ë°, ê·¸ê³³ì—ì„œ ì–‘í˜¸í•œ ìµœì¢… ì‹œì¥ ì„±ì¥ì„ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 4: Our market share is increasing, but because we have a distributor in that market, in the first year of sales, which was in 2024, we sold into that distributor. What we've been pretty clear about is that for the first part of 2025, we expect that distributor is gonna sell out some of that product that we sold. And so we do not expect to have sales into that distributor in the first<br><br>half of the year, but that's really a normal dynamic you see as any distributor setting up in a market. But overall, I think Asia is feeling pretty good. Similar with EMEA, I think it's feeling better than it's been.</td><td>ë°œí‘œì 4: ì €í¬ ì‹œì¥ ì ìœ ìœ¨ì€ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, í•´ë‹¹ ì‹œì¥ì— ìœ í†µì—…ì²´ê°€ ìˆê¸° ë•Œë¬¸ì— 2024ë…„ ì²« íŒë§¤ ì—°ë„ì—ëŠ” ê·¸ ìœ í†µì—…ì²´ì— íŒë§¤í–ˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ëª…í™•íˆ ë°íŒ ë°”ì™€ ê°™ì´, 2025ë…„ ìƒë°˜ê¸°ì—ëŠ” ìœ í†µì—…ì²´ê°€ ì €í¬ê°€ íŒë§¤í•œ ì œí’ˆ ì¤‘ ì¼ë¶€ë¥¼ ì†Œì§„í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìƒë°˜ê¸°ì—ëŠ” í•´ë‹¹ ìœ í†µì—…ì²´ì— ëŒ€í•œ ë§¤ì¶œì´ ì—†ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ì´ëŠ” ì–´ë–¤ ìœ í†µì—…ì²´ë“  ì‹œì¥ì— ì§„ì…í•  ë•Œ ë³´ì´ëŠ” ì •ìƒì ì¸ ì—­í•™ê´€ê³„ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì „ë°˜ì ìœ¼ë¡œ ì•„ì‹œì•„ ì§€ì—­ì€ ìƒë‹¹íˆ ì¢‹ì€ ìƒí™©ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. EMEA ì§€ì—­ë„ ë§ˆì°¬ê°€ì§€ë¡œ ì´ì „ë³´ë‹¤ ë‚˜ì•„ì§€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 4: There's still some pockets of softness in some markets, but overall it feels pretty stable. It's not improving a bit. And then Latin America remains a little bit of a, it's the one, it's the difficult region frankly of the three, right? And we've seen really dramatic slowdown in demand really across aesthetics in that market over the last eighteen months or so. In the fourth quarter, we did see some stability in in the markets, and so we don't feel like it's declining. Speaker 4: But at this point, we're not really projecting much of an increase either, so we're gonna watch it. But Latin America remains a little bit of a struggle. Speaker 1: Okay.</td><td>í™”ì 4: ì¼ë¶€ ì‹œì¥ì—ì„œëŠ” ì—¬ì „íˆ ë¶€ë¶„ì ì¸ ì•½ì„¸ê°€ ìˆì§€ë§Œ, ì „ë°˜ì ìœ¼ë¡œëŠ” ê½¤ ì•ˆì •ì ì¸ ëŠë‚Œì…ë‹ˆë‹¤. ì¡°ê¸ˆì”© ê°œì„ ë˜ê³  ìˆì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¼í‹´ ì•„ë©”ë¦¬ì¹´ëŠ” ì—¬ì „íˆ ì¡°ê¸ˆ, ì†”ì§íˆ ë§í•´ì„œ ì„¸ ì§€ì—­ ì¤‘ì—ì„œ ì–´ë ¤ìš´ ì§€ì—­ì´ì£ , ê·¸ë ‡ì£ ? ì§€ë‚œ 18ê°œì›” ì •ë„ ë™ì•ˆ í•´ë‹¹ ì‹œì¥ì—ì„œ ë¯¸ìš© ì „ë°˜ì— ê±¸ì³ ì •ë§ ê·¹ì ì¸ ìˆ˜ìš” ë‘”í™”ë¥¼ ë³´ì•˜ìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì—ëŠ” ì‹œì¥ì—ì„œ ì–´ëŠ ì •ë„ ì•ˆì •ì„¸ë¥¼ ë³´ì˜€ê³ , ë”°ë¼ì„œ í•˜ë½í•˜ê³  ìˆë‹¤ê³ ëŠ” ëŠë¼ì§€ ì•ŠìŠµë‹ˆë‹¤. <br><br>í™”ì 4: í•˜ì§€ë§Œ í˜„ì¬ë¡œì„œëŠ” í° ì¦ê°€ë„ ì‹¤ì œë¡œ ì˜ˆìƒí•˜ì§€ ì•Šê³  ìˆì–´ì„œ, ì§€ì¼œë³¼ ì˜ˆì •ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë¼í‹´ ì•„ë©”ë¦¬ì¹´ëŠ” ì—¬ì „íˆ ì¡°ê¸ˆ ì–´ë ¤ìš´ ìƒí™©ì…ë‹ˆë‹¤.<br><br>í™”ì 1: ì•Œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>How do you measure progress in those particular it's really frankly very hard for me sitting here in, you know, in The United States and in New York City. Speaker 3: So I think one of the most important metrics is market share. Okay. So, you know, when when markets are down, what you wanna do is make it an opportunity to take market share from others. And then when markets recover, then it gives you an extra push. So that's one thing we're constantly looking at is, you know, the number of accounts, our, accounts growing or not.</td><td>íŠ¹ì • ë¶„ì•¼ì—ì„œ ì§„ì „ì„ ì–´ë–»ê²Œ ì¸¡ì •í•˜ëŠ”ì§€ì— ëŒ€í•´ì„œëŠ”, ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ ë¯¸êµ­, ë‰´ìš•ì— ì•‰ì•„ ìˆëŠ” ì €ë¡œì„œëŠ” ì •ë§ ì–´ë ¤ìš´ ë¶€ë¶„ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ê°€ì¥ ì¤‘ìš”í•œ ì§€í‘œ ì¤‘ í•˜ë‚˜ëŠ” ì‹œì¥ì ìœ ìœ¨ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹œì¥ì´ ì¹¨ì²´ë˜ì—ˆì„ ë•Œ í•´ì•¼ í•  ì¼ì€ ì´ë¥¼ ê¸°íšŒë¡œ ì‚¼ì•„ ë‹¤ë¥¸ ì—…ì²´ë“¤ë¡œë¶€í„° ì‹œì¥ì ìœ ìœ¨ì„ ê°€ì ¸ì˜¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¬ë©´ ì‹œì¥ì´ íšŒë³µë  ë•Œ ì¶”ê°€ì ì¸ ì¶”ì§„ë ¥ì„ ì–»ê²Œ ë©ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ê°€ ì§€ì†ì ìœ¼ë¡œ ì£¼ì‹œí•˜ê³  ìˆëŠ” ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ê³„ì¢Œ ìˆ˜, ì¦‰ ì €í¬ ê³„ì¢Œê°€ ì¦ê°€í•˜ê³  ìˆëŠ”ì§€ ì—¬ë¶€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: One of the things that it's notable about Establishment Labs is that we've been able to create this pretty important network countries in which we sell into. I mean, we're talking about 90 countries wide including The United States and over time, you know, and we saw this during the pandemic, you know, you saw you see regions that, you know, are up, others are down. So it tends to, you know, as a whole, you know, be, you know, a positive for the<br><br>company. And that's when, you know, when you look at the low mid single digits, you know, growth for this year, it's an achievable target when you look at all the potential that we have.</td><td>ë°œí‘œì 3: Establishment Labsì˜ ì£¼ëª©í•  ë§Œí•œ íŠ¹ì§• ì¤‘ í•˜ë‚˜ëŠ” ì €í¬ê°€ íŒë§¤í•˜ëŠ” êµ­ê°€ë“¤ë¡œ êµ¬ì„±ëœ ìƒë‹¹íˆ ì¤‘ìš”í•œ ë„¤íŠ¸ì›Œí¬ë¥¼ êµ¬ì¶•í•  ìˆ˜ ìˆì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë¯¸êµ­ì„ í¬í•¨í•´ 90ê°œêµ­ì— ì´ë¥´ëŠ” ê´‘ë²”ìœ„í•œ ì‹œì¥ì—ì„œ ì‚¬ì—…ì„ ì „ê°œí•˜ê³  ìˆìœ¼ë©°, ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ, ê·¸ë¦¬ê³  íŒ¬ë°ë¯¹ ê¸°ê°„ ë™ì•ˆ ì €í¬ê°€ ëª©ê²©í–ˆë“¯ì´, ì–´ë–¤ ì§€ì—­ì€ ì„±ì¥í•˜ê³  ë‹¤ë¥¸ ì§€ì—­ì€ í•˜ë½í•˜ëŠ” ëª¨ìŠµì„ ë³´ê²Œ ë©ë‹ˆë‹¤. ë”°ë¼ì„œ ì „ì²´ì ìœ¼ë¡œ ë³´ë©´ íšŒì‚¬ì—ê²ŒëŠ” ê¸ì •ì ì¸ ìš”ì†Œê°€ ë˜ëŠ” ê²½í–¥ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ì‚´í´ë³´ë©´, ì €í¬ê°€ ê°€ì§„ ëª¨ë“  ì ì¬ë ¥ì„ ê³ ë ¤í•  ë•Œ ë‹¬ì„± ê°€ëŠ¥í•œ ëª©í‘œë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>You know, it doesn't include new product launches like Preserve. Speaker 3: It doesn't include, like, the halo effect that the FDA approval has been having on our, you know, OUS business. So there's a lot of things that can go positive within the macroeconomic softness that you might see in countries. And maybe just<br><br>Speaker 4: adding to that point too, what what JJ was saying in terms of this market share gaining strategy we have. You know, if you look over the last eighteen months in some of these markets around the world, there was softness. I mean, clearly, it's not just us.</td><td>ì•Œê² ìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì„ ìì—°ìŠ¤ëŸ¬ìš´ í•œêµ­ì–´ë¡œ ë²ˆì—­í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Speaker 3: ì´ ìˆ˜ì¹˜ì—ëŠ” Preserveì™€ ê°™ì€ ì‹ ì œí’ˆ ì¶œì‹œë„ í¬í•¨ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë˜í•œ FDA ìŠ¹ì¸ì´ ìš°ë¦¬ í•´ì™¸ ì‚¬ì—…ì— ë¯¸ì¹˜ê³  ìˆëŠ” í›„ê´‘ íš¨ê³¼ë„ í¬í•¨ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê°êµ­ì—ì„œ ê±°ì‹œê²½ì œì  ì—°ì°©ë¥™ì´ ë‚˜íƒ€ë‚  ìˆ˜ ìˆëŠ” ìƒí™©ì—ì„œë„ ê¸ì •ì ìœ¼ë¡œ ì‘ìš©í•  ìˆ˜ ìˆëŠ” ìš”ì†Œë“¤ì´ ë§ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ë§ˆë„...<br><br>Speaker 4: ê·¸ ë¶€ë¶„ì— ë§ë¶™ì—¬ì„œ, JJê°€ ë§í•œ ì‹œì¥ì ìœ ìœ¨ í™•ëŒ€ ì „ëµê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì§€ë‚œ 18ê°œì›” ë™ì•ˆ ì „ ì„¸ê³„ ì¼ë¶€ ì‹œì¥ë“¤ì„ ì‚´í´ë³´ë©´ ì—°ì°©ë¥™ í˜„ìƒì´ ìˆì—ˆìŠµë‹ˆë‹¤. ë¶„ëª…íˆ ì´ëŠ” ìš°ë¦¬ë§Œì˜ ë¬¸ì œê°€ ì•„ë‹™ë‹ˆë‹¤.</td></tr>
<tr><td>Know, you look at luxury goods, you look at other aesthetic companies, you know, these markets have been a little challenging. And yet in the face of that, we were able to still put up growth in all of our markets. Speaker 4: And so, we are taking share. It's pretty clear against, you know, pretty difficult backdrop over the last eighteen months. And again, it's feeling a bit better as we're moving here into 2025, but but certainly last eighteen months, we've we've outperformed our markets. Speaker 1: One of the things I was impressed by last evening was when you were talking about market share in certain regions. And, I think it's worth sort of pausing on that.</td><td>ëŸ­ì…”ë¦¬ ìƒí’ˆì´ë‚˜ ë‹¤ë¥¸ ë¯¸ìš© íšŒì‚¬ë“¤ì„ ë³´ë©´, ì´ëŸ° ì‹œì¥ë“¤ì´ ë‹¤ì†Œ ì–´ë ¤ìš´ ìƒí™©ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ì´ëŸ° ìƒí™©ì—ì„œë„ ì €í¬ëŠ” ëª¨ë“  ì‹œì¥ì—ì„œ ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë”°ë¼ì„œ ì €í¬ëŠ” ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ 18ê°œì›”ê°„ ìƒë‹¹íˆ ì–´ë ¤ìš´ í™˜ê²½ ì†ì—ì„œë„ ì´ëŠ” ë§¤ìš° ëª…í™•í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  2025ë…„ìœ¼ë¡œ ì ‘ì–´ë“¤ë©´ì„œ ìƒí™©ì´ ë‹¤ì†Œ ë‚˜ì•„ì§€ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ëŠê»´ì§€ì§€ë§Œ, í™•ì‹¤íˆ ì§€ë‚œ 18ê°œì›” ë™ì•ˆ ì €í¬ëŠ” ì‹œì¥ì„ ëŠ¥ê°€í•˜ëŠ” ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì–´ì œ ì €ë…ì— íŠ¹ì • ì§€ì—­ì—ì„œì˜ ì‹œì¥ ì ìœ ìœ¨ì— ëŒ€í•´ ë§ì”€í•˜ì‹¤ ë•Œ ì¸ìƒ ê¹Šì—ˆë˜ ì  ì¤‘ í•˜ë‚˜ê°€ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ë¶€ë¶„ì— ëŒ€í•´ ì ì‹œ ì§šê³  ë„˜ì–´ê°ˆ ê°€ì¹˜ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I mean, you have majority share and I think it was Thailand and a couple of other areas, but I'll leave it for you to remind. Speaker 3: No. I think what we wanted yesterday is some reference points of markets that have you know, characteristics that may be similar to The US, for instance, you know, that most of those markets are smooth implant markets, high priced. And, you know, we refer to Taiwan, to Switzerland and to Korea as good reference points of how we grew our market share over time. And for instance, Taiwan has been our latest launch in country. The majority of the Taiwanese surgeons are U. Speaker 3: S. Trained.</td><td>ì œ ë§ì€, ê·€í•˜ê°€ íƒœêµ­ê³¼ ëª‡ëª‡ ë‹¤ë¥¸ ì§€ì—­ì—ì„œ ê³¼ë°˜ ì§€ë¶„ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ìƒê°í•˜ëŠ”ë°, ì´ ë¶€ë¶„ì€ ê·€í•˜ê°€ ì§ì ‘ ì„¤ëª…í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>í™”ì 3: ì•„ë‹™ë‹ˆë‹¤. ì €í¬ê°€ ì–´ì œ ì›í–ˆë˜ ê²ƒì€ ë¯¸êµ­ê³¼ ìœ ì‚¬í•œ íŠ¹ì„±ì„ ê°€ì§ˆ ìˆ˜ ìˆëŠ” ì‹œì¥ë“¤ì˜ ì°¸ê³  ì§€ì ë“¤ì´ì—ˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ê·¸ëŸ¬í•œ ì‹œì¥ë“¤ ëŒ€ë¶€ë¶„ì€ ë§¤ë„ëŸ¬ìš´ ì„í”Œë€íŠ¸ ì‹œì¥ì´ë©° ê³ ê°€ê²©ëŒ€ ì‹œì¥ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì‹œì¥ ì ìœ ìœ¨ì„ ì–´ë–»ê²Œ ì„±ì¥ì‹œì¼°ëŠ”ì§€ì— ëŒ€í•œ ì¢‹ì€ ì°¸ê³  ì§€ì ìœ¼ë¡œ ëŒ€ë§Œ, ìŠ¤ìœ„ìŠ¤, ê·¸ë¦¬ê³  í•œêµ­ì„ ì–¸ê¸‰í–ˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ëŒ€ë§Œì€ ì €í¬ì˜ ê°€ì¥ ìµœê·¼ ì¶œì‹œ êµ­ê°€ì…ë‹ˆë‹¤. ëŒ€ë§Œ ì™¸ê³¼ì˜ì‚¬ë“¤ì˜ ëŒ€ë‹¤ìˆ˜ëŠ” ë¯¸êµ­ì—ì„œ í›ˆë ¨ë°›ì•˜ìŠµë‹ˆë‹¤.<br><br>í™”ì 3: ë¯¸êµ­ì—ì„œ í›ˆë ¨ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And what we have seen is a pretty linear increase of our market share over the first four years from 0% to 40% market share. And when we look at The US market, we absolutely believe that there is an opportunity for us to eventually get to the market share numbers that we are seeing in those reference markets. Speaker 1: So let's talk about The US launch. What has surprised you and what has not surprised you? Speaker 3: Probably, I think the the most important things for us has been, you know, the level of excitement of The US Plastic Surgery community.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ í™•ì¸í•œ ê²ƒì€ ì²˜ìŒ 4ë…„ ë™ì•ˆ ì‹œì¥ ì ìœ ìœ¨ì´ 0%ì—ì„œ 40%ê¹Œì§€ ìƒë‹¹íˆ ì„ í˜•ì ìœ¼ë¡œ ì¦ê°€í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ ì‹œì¥ì„ ì‚´í´ë³¼ ë•Œ, ìš°ë¦¬ëŠ” ê²°êµ­ ì´ëŸ¬í•œ ì°¸ì¡° ì‹œì¥ì—ì„œ ë³´ê³  ìˆëŠ” ì‹œì¥ ì ìœ ìœ¨ ìˆ˜ì¤€ì— ë„ë‹¬í•  ê¸°íšŒê°€ ë¶„ëª…íˆ ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ê·¸ëŸ¼ ë¯¸êµ­ ì¶œì‹œì— ëŒ€í•´ ì´ì•¼ê¸°í•´ ë³´ê² ìŠµë‹ˆë‹¤. ë¬´ì—‡ì´ ì˜ˆìƒê³¼ ë‹¬ëê³ , ë¬´ì—‡ì´ ì˜ˆìƒëŒ€ë¡œì˜€ë‚˜ìš”?<br><br>ë°œí‘œì 3: ì•„ë§ˆë„ ìš°ë¦¬ì—ê²Œ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ë¯¸êµ­ ì„±í˜•ì™¸ê³¼ ì»¤ë®¤ë‹ˆí‹°ì˜ ê´€ì‹¬ ìˆ˜ì¤€ì´ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I think that has been fantastic for us in terms of like, how quickly they've been able to really verbalize the attributes and benefits to patients of our technology. And in that, you know, perhaps our biggest risk factor was, you know, how was, you know, our our biggest competitor, Appy, was going to use their bundle against our technology. And, and frankly, it has not been an issue at all, which shows you the power up technology.</td><td>ì €í¬ì—ê²Œ ì •ë§ í™˜ìƒì ì´ì—ˆë˜ ê²ƒì€ ê·¸ë“¤ì´ ì–¼ë§ˆë‚˜ ë¹ ë¥´ê²Œ ì €í¬ ê¸°ìˆ ì˜ íŠ¹ì„±ê³¼ í™˜ìë“¤ì—ê²Œ ì£¼ëŠ” ì´ìµì„ ëª…í™•í•˜ê²Œ ì„¤ëª…í•  ìˆ˜ ìˆì—ˆëŠ”ì§€ í•˜ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ë§ˆë„ ì €í¬ì˜ ê°€ì¥ í° ë¦¬ìŠ¤í¬ ìš”ì¸ì€ ì €í¬ì˜ ìµœëŒ€ ê²½ìŸì‚¬ì¸ Appyê°€ ìì‚¬ì˜ ë²ˆë“¤ì„ ì €í¬ ê¸°ìˆ ì— ëŒ€í•­í•´ì„œ ì–´ë–»ê²Œ í™œìš©í•  ê²ƒì¸ê°€ í•˜ëŠ” ë¶€ë¶„ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ê·¸ê²ƒì€ ì „í˜€ ë¬¸ì œê°€ ë˜ì§€ ì•Šì•˜ìœ¼ë©°, ì´ëŠ” ì €í¬ ê¸°ìˆ ë ¥ì˜ ê°•ë ¥í•¨ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>The fact that they would come in and tell plastic surgeons, don't use that technology because I'm gonna lower your prices here and there, has not really had an effect on the decision making process of these plastic surgeons, which tells you number one, the importance of safety and our safety numbers from our US clinical trial and second, the new options like, you know, putting the implant above the muscle, which is not something that was commonly done in The US because of capsular contracture. Speaker 3: So these things are probably, I would say, when you think about like the long term leadership of our technology in The US, some of the most important things.</td><td>ê·¸ë“¤ì´ ì™€ì„œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì—ê²Œ "ê·¸ ê¸°ìˆ ì„ ì‚¬ìš©í•˜ì§€ ë§ë¼, ìš°ë¦¬ê°€ ì—¬ê¸°ì €ê¸°ì„œ ê°€ê²©ì„ ë‚®ì¶°ì£¼ê² ë‹¤"ê³  ë§í•œë‹¤ê³  í•´ì„œ ì´ëŸ¬í•œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì˜ ì˜ì‚¬ê²°ì • ê³¼ì •ì— ì‹¤ì§ˆì ì¸ ì˜í–¥ì„ ë¯¸ì¹˜ì§€ëŠ” ëª»í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì²«ì§¸ë¡œ ì•ˆì „ì„±ì˜ ì¤‘ìš”ì„±ê³¼ ìš°ë¦¬ ë¯¸êµ­ ì„ìƒì‹œí—˜ì˜ ì•ˆì „ì„± ìˆ˜ì¹˜, ê·¸ë¦¬ê³  ë‘˜ì§¸ë¡œ ê·¼ìœ¡ ìœ„ì— ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•˜ëŠ” ê²ƒê³¼ ê°™ì€ ìƒˆë¡œìš´ ì˜µì…˜ë“¤ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ëŠ” í”¼ë§‰ êµ¬ì¶• ë•Œë¬¸ì— ë¯¸êµ­ì—ì„œëŠ” ì¼ë°˜ì ìœ¼ë¡œ ì‹œí–‰ë˜ì§€ ì•Šì•˜ë˜ ë°©ë²•ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë”°ë¼ì„œ ì´ëŸ¬í•œ ìš”ì†Œë“¤ì€ ì•„ë§ˆë„, ë¯¸êµ­ì—ì„œ ìš°ë¦¬ ê¸°ìˆ ì˜ ì¥ê¸°ì  ë¦¬ë”ì‹­ì„ ìƒê°í•´ë³¼ ë•Œ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒë“¤ ì¤‘ ì¼ë¶€ë¼ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 2: Just to add to that, you know, I think as JJ mentioned, I mean, the excitement for<br><br>what we're seeing in the marketplace, because in in essence, it's been starving for any type of new news and innovation. And I think because of that, I think we were able to take advantage of of the the opportunity and with that, you know, type of excitement. And and I think, also, going into it, we're very confident. I think it's really exceeded our expectations. And we've been able<br>to put together a world class organization, and we've made sure as we talk about, you know, managing the operating expenses, that was around the corporate, but we've fully funded, The US business.</td><td>ë°œí‘œì 2: ê·¸ê²ƒì— ë§ë¶™ì—¬ì„œ, JJê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì‹œì¥ì—ì„œ ë³´ê³  ìˆëŠ” ê²ƒì— ëŒ€í•œ í¥ë¶„ê°ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë³¸ì§ˆì ìœ¼ë¡œ ì‹œì¥ì´ ì–´ë–¤ í˜•íƒœì˜ ìƒˆë¡œìš´ ì†Œì‹ê³¼ í˜ì‹ ì— ëª©ë§ë¼ ìˆì—ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ë•Œë¬¸ì— ìš°ë¦¬ê°€ ê·¸ ê¸°íšŒë¥¼ í™œìš©í•  ìˆ˜ ìˆì—ˆê³ , ê·¸ëŸ° ì¢…ë¥˜ì˜ í¥ë¶„ê°ê³¼ í•¨ê»˜ ë§ì´ì£ . ë˜í•œ ì´ ì¼ì— ì°©ìˆ˜í•˜ë©´ì„œ ìš°ë¦¬ëŠ” ë§¤ìš° í™•ì‹ í–ˆìŠµë‹ˆë‹¤. ì •ë§ë¡œ ìš°ë¦¬ì˜ ê¸°ëŒ€ë¥¼ ë›°ì–´ë„˜ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì„¸ê³„ì  ìˆ˜ì¤€ì˜ ì¡°ì§ì„ êµ¬ì„±í•  ìˆ˜ ìˆì—ˆê³ , ìš´ì˜ë¹„ìš© ê´€ë¦¬ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ë•Œ - ê·¸ê²ƒì€ ê¸°ì—… ì°¨ì›ì—ì„œì˜ ê²ƒì´ì—ˆì§€ë§Œ - ë¯¸êµ­ ì‚¬ì—…ì—ëŠ” ì¶©ë¶„í•œ ìê¸ˆì„ ì§€ì›í–ˆë‹¤ëŠ” ì ì„ í™•ì‹¤íˆ í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 2: And and I think we continue to put ourselves in a position to maximize that opportunity by giving it the resources that it that it needs. Speaker 1: So one of the things as being a student of med tech for a while is that companies usually lean in on their expenses as they're launching a a new product, and yet you're managing pulling back on expenses while you launch<br><br>Speaker 2: Well, it's it's where we're pulling back. So we pull back from a corporate so we were very surgical in terms of how we manage the expense. We actually reduced a lot of expenses from a corporate standpoint.</td><td>**í™”ì 2:** ê·¸ë¦¬ê³  ì €í¬ëŠ” í•„ìš”í•œ ìì›ì„ ì œê³µí•¨ìœ¼ë¡œì¨ ê·¸ ê¸°íšŒë¥¼ ê·¹ëŒ€í™”í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ê³„ì†í•´ì„œ ìë¦¬ì¡ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>**í™”ì 1:** ì˜ë£Œê¸°ê¸° ë¶„ì•¼ë¥¼ ì˜¤ë«ë™ì•ˆ ì§€ì¼œë³¸ ì…ì¥ì—ì„œ ë³´ë©´, ê¸°ì—…ë“¤ì€ ë³´í†µ ì‹ ì œí’ˆì„ ì¶œì‹œí•  ë•Œ ë¹„ìš©ì„ ëŠ˜ë¦¬ëŠ” ê²½í–¥ì´ ìˆëŠ”ë°, ê·€í•˜ëŠ” ì œí’ˆ ì¶œì‹œì™€ ë™ì‹œì— ë¹„ìš©ì„ ì¤„ì´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>**í™”ì 2:** ì–´ë””ì„œ ë¹„ìš©ì„ ì¤„ì´ëŠëƒê°€ ì¤‘ìš”í•©ë‹ˆë‹¤. ì €í¬ëŠ” ê¸°ì—… ì°¨ì›ì—ì„œ ë¹„ìš©ì„ ì¤„ì˜€ìŠµë‹ˆë‹¤. ë¹„ìš© ê´€ë¦¬ ë°©ì‹ì—ì„œ ë§¤ìš° ì „ëµì ìœ¼ë¡œ ì ‘ê·¼í–ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ê¸°ì—… ìš´ì˜ ì¸¡ë©´ì—ì„œ ë§ì€ ë¹„ìš©ì„ ì ˆê°í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I think, you know, as we looked at the overall business, we thought maybe we're a little bit large in that area, so there were certainly opportunities. But we were very clear in terms of where we're gonna put our resources, and the number one priority was to to put it in The US. Speaker 2: So in essence, a lot of this was reducing the expenses. It was reallocating the resources where we saw the greatest opportunity. So I don't think in any area that we kind of shortchange the opportunity in The US. Actually, I think we did the opposite. Speaker 1: So you've built a Salesforce, at the stage up to forty, fifty, 40, individuals.</td><td>ì „ì²´ ì‚¬ì—…ì„ ê²€í† í•´ë³´ë‹ˆ, í•´ë‹¹ ì˜ì—­ì—ì„œ ê·œëª¨ê°€ ë‹¤ì†Œ í° í¸ì´ë¼ê³  íŒë‹¨í–ˆê³ , ë¶„ëª…íˆ ê¸°íšŒê°€ ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìì›ì„ ì–´ë””ì— íˆ¬ì…í• ì§€ì— ëŒ€í•´ì„œëŠ” ë§¤ìš° ëª…í™•í–ˆê³ , ìµœìš°ì„  ìˆœìœ„ëŠ” ë¯¸êµ­ì— íˆ¬ì…í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤.<br><br>í™”ì 2: ë³¸ì§ˆì ìœ¼ë¡œ ì´ëŠ” ëŒ€ë¶€ë¶„ ë¹„ìš© ì ˆê°ì´ì—ˆìŠµë‹ˆë‹¤. ê°€ì¥ í° ê¸°íšŒë¥¼ ë³´ëŠ” ê³³ìœ¼ë¡œ ìì›ì„ ì¬ë°°ì¹˜í•˜ëŠ” ê²ƒì´ì—ˆì£ . ë¯¸êµ­ì—ì„œì˜ ê¸°íšŒë¥¼ ì†Œí™€íˆ í•œ ì˜ì—­ì€ ì—†ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹¤ì œë¡œëŠ” ê·¸ ë°˜ëŒ€ì˜€ë‹¤ê³  ë´…ë‹ˆë‹¤.<br><br>í™”ì 1: ê·¸ë˜ì„œ ì˜ì—…íŒ€ì„ êµ¬ì¶•í•˜ì—¬ í˜„ì¬ 40ëª…, 50ëª…, 40ëª… ì •ë„ì˜ ì¸ë ¥ì„ ê°–ì¶”ê³  ê³„ì‹œëŠ”êµ°ìš”.</td></tr>
<tr><td>And one of the things we're thinking about last night is you're look looking to expand beyond that, but not<br><br>necessarily dramatically if I if I understand their messaging correctly. Speaker 3: That is correct. And I think, it's it's also about the quality of the of, you know, our commercial team. And, you know, we're sitting at, you know, with 40 sales reps. And throughout this year, you know, in certain metro areas as we, you know, increase the number of accounts in those areas, we may add, a sales rep here and there, opportunistically and depending on the situation. But we feel very comfortable with the team that we have right now.</td><td>ì–´ì ¯ë°¤ì— ìš°ë¦¬ê°€ ìƒê°í•´ë³¸ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ê·€í•˜ê»˜ì„œ ê·¸ ë²”ìœ„ë¥¼ ë„˜ì–´ í™•ì¥í•˜ë ¤ê³  í•˜ì‹œì§€ë§Œ, ì œê°€ ê·¸ë“¤ì˜ ë©”ì‹œì§€ë¥¼ ì˜¬ë°”ë¥´ê²Œ ì´í•´í–ˆë‹¤ë©´ ë°˜ë“œì‹œ ê·¹ì ìœ¼ë¡œ í™•ì¥í•˜ë ¤ëŠ” ê²ƒì€ ì•„ë‹ˆë¼ëŠ” ì ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë§ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” ìš°ë¦¬ ì˜ì—…íŒ€ì˜ í’ˆì§ˆê³¼ë„ ê´€ë ¨ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í˜„ì¬ ì €í¬ëŠ” 40ëª…ì˜ ì˜ì—… ë‹´ë‹¹ìë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë‚´ë‚´ íŠ¹ì • ëŒ€ë„ì‹œ ì§€ì—­ì—ì„œ í•´ë‹¹ ì§€ì—­ì˜ ê³ ê°ì‚¬ ìˆ˜ê°€ ì¦ê°€í•¨ì— ë”°ë¼ ìƒí™©ì— ë”°ë¼ ê¸°íšŒê°€ ë˜ë©´ ì˜ì—… ë‹´ë‹¹ìë¥¼ í•œë‘ ëª…ì”© ì¶”ê°€í•  ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ í˜„ì¬ ë³´ìœ í•œ íŒ€ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: We don't think that there's an urgent need to expand that group to be able to achieve our 35,000,000 target for 2025. Speaker 1: So let's talk about how do you achieve that 35,000,000 target. What's the pathway from 3.3 in the fourth quarter to guidance, I think, of five and a half in the first quarter to get to the full year guide. Speaker 3: Well, I<br><br><br>Speaker 4: think one of the, one of the metrics we provided yesterday was the daily sales we're seeing and the ramp we're seeing in that in those. And what we talked about is, you know, in in, in January, we were averaging about 70 orders per day. February, we're at 90 orders per day.</td><td>**Speaker 3:** 2025ë…„ 3,500ë§Œ ë‹¬ëŸ¬ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•´ í•´ë‹¹ ê·¸ë£¹ì„ í™•ì¥í•´ì•¼ í•  ê¸´ê¸‰í•œ í•„ìš”ì„±ì€ ì—†ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>**Speaker 1:** ê·¸ë ‡ë‹¤ë©´ 3,500ë§Œ ë‹¬ëŸ¬ ëª©í‘œë¥¼ ì–´ë–»ê²Œ ë‹¬ì„±í•  ê²ƒì¸ì§€ì— ëŒ€í•´ ì´ì•¼ê¸°í•´ ë³´ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° 330ë§Œ ë‹¬ëŸ¬ì—ì„œ 1ë¶„ê¸° ê°€ì´ë˜ìŠ¤ì¸ 550ë§Œ ë‹¬ëŸ¬ë¥¼ ê±°ì³ ì—°ê°„ ê°€ì´ë˜ìŠ¤ì— ë„ë‹¬í•˜ëŠ” ê²½ë¡œëŠ” ë¬´ì—‡ì…ë‹ˆê¹Œ?<br><br>**Speaker 3:** ìŒ, ì €ëŠ”...<br><br>**Speaker 4:** ì–´ì œ ì €í¬ê°€ ì œê³µí•œ ì§€í‘œ ì¤‘ í•˜ë‚˜ëŠ” í˜„ì¬ ë³´ê³  ìˆëŠ” ì¼ì¼ ë§¤ì¶œê³¼ ê·¸ ìƒìŠ¹ì„¸ì˜€ìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, 1ì›”ì—ëŠ” í•˜ë£¨ í‰ê·  ì•½ 70ê±´ì˜ ì£¼ë¬¸ì„ ê¸°ë¡í–ˆê³ , 2ì›”ì—ëŠ” í•˜ë£¨ 90ê±´ì˜ ì£¼ë¬¸ì„ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And if you do the math just simply on, you know, what 90 orders per day is, you know, that's two big plants at the ASPs we charge. You know, the runway we're on, and again, we're still only four months into the launch, you know, gives you a pretty good line of sight that, you<br>know, achieving that that target even if nothing improves from here is likely doable. Speaker 4: Right? And as, JJ and Pete mentioned, the enthusiasm and the the interest we're seeing from the community in The United States. I mean, it's only building. Right? And so we do expect that metric will continue to go higher.</td><td>ë‹¨ìˆœíˆ ê³„ì‚°í•´ë³´ë©´, í•˜ë£¨ 90ê±´ì˜ ì£¼ë¬¸ì´ ë¬´ì—‡ì„ ì˜ë¯¸í•˜ëŠ”ì§€ ì•„ì‹œê² ì§€ë§Œ, ì´ëŠ” ì €í¬ê°€ ì±…ì •í•œ í‰ê·  íŒë§¤ê°€ê²©(ASP) ê¸°ì¤€ìœ¼ë¡œ ëŒ€í˜• í”ŒëœíŠ¸ 2ê°œ ê·œëª¨ì…ë‹ˆë‹¤. ì €í¬ê°€ í˜„ì¬ ì§„í–‰í•˜ê³  ìˆëŠ” ê¶¤ë„ë¥¼ ë³´ë©´, ê·¸ë¦¬ê³  ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ ì¶œì‹œí•œ ì§€ ì•„ì§ 4ê°œì›”ë°–ì— ë˜ì§€ ì•Šì•˜ëŠ”ë°ë„, ì—¬ê¸°ì„œ ì•„ë¬´ê²ƒë„ ê°œì„ ë˜ì§€ ì•Šë”ë¼ë„ í•´ë‹¹ ëª©í‘œë¥¼ ë‹¬ì„±í•  ê°€ëŠ¥ì„±ì´ ë†’ë‹¤ëŠ” ê²ƒì„ ì¶©ë¶„íˆ ì˜ˆì¸¡í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë§ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  JJì™€ Peteê°€ ì–¸ê¸‰í–ˆë“¯ì´, ë¯¸êµ­ ë‚´ ì»¤ë®¤ë‹ˆí‹°ì—ì„œ ë³´ì´ê³  ìˆëŠ” ì—´ì •ê³¼ ê´€ì‹¬ì´ ê³„ì†í•´ì„œ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì´ ì§€í‘œê°€ ê³„ì†í•´ì„œ ìƒìŠ¹í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 4: And so it's really about, you know, signing up accounts, but then it's also about getting that that, that pull through, that utilization, the reordering patterns, and all of that so far has been very, very positive for us. Speaker 1: I think there's an impression amongst investors that most of the physicians that are right now are on the coasts, and there's there's just a handful of high volume folks that are just really embracing it. Is that the right perception? Speaker 3: Well, we are very happy with some of our biggest accounts. I think it's a it's a testament to, you know, the power of, of our technology. But when you look at six fifty accounts, that's not a small number.</td><td>**ë°œí‘œì 4:** ê·¸ë˜ì„œ ì‹¤ì œë¡œëŠ” ê³„ì •ì„ í™•ë³´í•˜ëŠ” ê²ƒë¿ë§Œ ì•„ë‹ˆë¼, ê·¸ í›„ì† íš¨ê³¼, ì¦‰ í™œìš©ë„, ì¬ì£¼ë¬¸ íŒ¨í„´ ë“±ì„ ì–»ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ì´ ëª¨ë“  ê²ƒë“¤ì´ ì €í¬ì—ê²Œ ë§¤ìš°, ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>**ë°œí‘œì 1:** íˆ¬ììë“¤ ì‚¬ì´ì—ì„œëŠ” í˜„ì¬ ëŒ€ë¶€ë¶„ì˜ ì˜ì‚¬ë“¤ì´ ì—°ì•ˆ ì§€ì—­ì— ìˆê³ , ì†Œìˆ˜ì˜ ê³ ìš©ëŸ‰ ì˜ì‚¬ë“¤ë§Œì´ ì´ ê¸°ìˆ ì„ ì ê·¹ì ìœ¼ë¡œ ë°›ì•„ë“¤ì´ê³  ìˆë‹¤ëŠ” ì¸ìƒì´ ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¸ì‹ì´ ë§ìŠµë‹ˆê¹Œ?<br><br>**ë°œí‘œì 3:** ì €í¬ëŠ” ì¼ë¶€ ëŒ€í˜• ê³„ì •ë“¤ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì €í¬ ê¸°ìˆ ì˜ í˜ì„ ë³´ì—¬ì£¼ëŠ” ì¦ê±°ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ 650ê°œ ê³„ì •ì„ ë³´ë©´, ì´ëŠ” ê²°ì½” ì ì€ ìˆ«ìê°€ ì•„ë‹™ë‹ˆë‹¤.</td></tr>
<tr><td>Yeah. And that is only in four months. Speaker 1: Yeah. Speaker 3: So I think, you know, when you when you see the ramp in the number of accounts that we gather, you know, all over the country, I think it's a it's a good sign of how this ramps up. So, you know, of course, you still have part of the accounts that are yet to come over, more conservative, perhaps, you know, haven't had the time to speak to their peers about their early experience, but we're going to have those opportunities. In March, we have the American Society of Plastic Surgeons meeting in Austin. That's the biggest aesthetic meeting for plastic surgeons in the year. We're going to have many opportunities there.</td><td>ë„¤. ê·¸ë¦¬ê³  ê·¸ê²ƒì€ ë‹¨ 4ê°œì›” ë§Œì˜ ì„±ê³¼ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ë„¤.<br><br>ë°œí‘œì 3: ë”°ë¼ì„œ ì „êµ­ì ìœ¼ë¡œ ìš°ë¦¬ê°€ í™•ë³´í•˜ëŠ” ê³„ì • ìˆ˜ì˜ ì¦ê°€ ì¶”ì´ë¥¼ ë³´ì‹œë©´, ì´ê²ƒì´ ì–´ë–»ê²Œ í™•ì‚°ë˜ê³  ìˆëŠ”ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ì¢‹ì€ ì‹ í˜¸ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡  ì•„ì§ ì „í™˜í•˜ì§€ ì•Šì€ ê³„ì •ë“¤ì´ ì¼ë¶€ ìˆìŠµë‹ˆë‹¤. ì•„ë§ˆë„ ë” ë³´ìˆ˜ì ì´ê±°ë‚˜, ë™ë£Œë“¤ì˜ ì´ˆê¸° ê²½í—˜ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ì‹œê°„ì´ ì—†ì—ˆì„ ìˆ˜ë„ ìˆì§€ë§Œ, ìš°ë¦¬ì—ê²ŒëŠ” ê·¸ëŸ° ê¸°íšŒë“¤ì´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. 3ì›”ì—ëŠ” ì˜¤ìŠ¤í‹´ì—ì„œ ë¯¸êµ­ì„±í˜•ì™¸ê³¼í•™íšŒ íšŒì˜ê°€ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì„ ìœ„í•œ ì—°ì¤‘ ê°€ì¥ í° ë¯¸ìš© ê´€ë ¨ íšŒì˜ì…ë‹ˆë‹¤. ê·¸ê³³ì—ì„œ ë§ì€ ê¸°íšŒë¥¼ ê°€ì§ˆ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: We're holding many events. So that's how many of these next group of accounts will take place because then they'll get reinforced by people who are already. Speaker 1: So what makes revenue go above your $35,000,000, guide, and what makes it go below? I sense this is a conservative number. Speaker 4: Well, we look at it as achievable, and and and we are doing everything we can to<br><br>beat it. You know, as as noted, we're still adding new accounts. You know, I think we yesterday, we talked about more than five accounts per day. We're still signing up.</td><td>Speaker 3: ì €í¬ëŠ” ë§ì€ ì´ë²¤íŠ¸ë¥¼ ê°œìµœí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ëŸ¬í•œ ë‹¤ìŒ ê·¸ë£¹ì˜ ê³„ì •ë“¤ ì¤‘ ë§ì€ ìˆ˜ê°€ ì´ë¯¸ ì°¸ì—¬í•˜ê³  ìˆëŠ” ì‚¬ëŒë“¤ì— ì˜í•´ ê°•í™”ë  ê²ƒì´ê¸° ë•Œë¬¸ì— ê·¸ëŸ° ì‹ìœ¼ë¡œ ì§„í–‰ë  ê²ƒì…ë‹ˆë‹¤.<br><br>Speaker 1: ë§¤ì¶œì´ ê·€í•˜ì˜ 3,500ë§Œ ë‹¬ëŸ¬ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒíšŒí•˜ê²Œ í•˜ëŠ” ìš”ì¸ê³¼ í•˜íšŒí•˜ê²Œ í•˜ëŠ” ìš”ì¸ì€ ë¬´ì—‡ì…ë‹ˆê¹Œ? ì´ ìˆ˜ì¹˜ê°€ ë³´ìˆ˜ì ì¸ ê²ƒ ê°™ë‹¤ëŠ” ëŠë‚Œì´ ë“­ë‹ˆë‹¤.<br><br>Speaker 4: ì €í¬ëŠ” ì´ë¥¼ ë‹¬ì„± ê°€ëŠ¥í•œ ìˆ˜ì¹˜ë¡œ ë³´ê³  ìˆìœ¼ë©°, ì´ë¥¼ ìƒíšŒí•˜ê¸° ìœ„í•´ í•  ìˆ˜ ìˆëŠ” ëª¨ë“  ê²ƒì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì €í¬ëŠ” ì—¬ì „íˆ ìƒˆë¡œìš´ ê³„ì •ì„ ì¶”ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì–´ì œ ë…¼ì˜í–ˆë“¯ì´ í•˜ë£¨ì— 5ê°œ ì´ìƒì˜ ê³„ì •ì„ ì—¬ì „íˆ ë“±ë¡í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I think it's important to note that, you know, when an account signs up, oftentimes, surgeons have already booked out their schedule sometimes months into the future. Speaker 4: And so some will do the work to go back and and change, cases they've already scheduled to swap another company's implants for hours, but some will not do that. And so in a sense, you're you're you're you're it takes a little while to ramp up into these practices, and so we're still early in that. And that gives us some confidence. I think the other really interesting aspect is that, you know, we have not, at this point, done any direct to consumer marketing or any work on our, that's sponsored directly by us.</td><td>ì¤‘ìš”í•œ ì ì€ ê³„ì •ì´ ê°€ì…í•  ë•Œ, ì™¸ê³¼ì˜ë“¤ì´ ì´ë¯¸ ëª‡ ë‹¬ ì•ê¹Œì§€ ìˆ˜ìˆ  ì¼ì •ì„ ì˜ˆì•½í•´ ë†“ì€ ê²½ìš°ê°€ ë§ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ê·¸ë˜ì„œ ì¼ë¶€ ì˜ì‚¬ë“¤ì€ ì´ë¯¸ ì˜ˆì•½ëœ ì¼€ì´ìŠ¤ë“¤ì„ ë‹¤ì‹œ ê²€í† í•˜ì—¬ ë‹¤ë¥¸ íšŒì‚¬ì˜ ì„í”Œë€íŠ¸ë¥¼ ì €í¬ ì œí’ˆìœ¼ë¡œ êµì²´í•˜ëŠ” ì‘ì—…ì„ í•˜ì§€ë§Œ, ê·¸ë ‡ê²Œ í•˜ì§€ ì•ŠëŠ” ì˜ì‚¬ë“¤ë„ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì–´ë–¤ ì˜ë¯¸ì—ì„œëŠ” ì´ëŸ¬í•œ ë³‘ì›ë“¤ì— ì§„ì…í•˜ì—¬ ë³¸ê²©ì ìœ¼ë¡œ ì„±ê³¼ë¥¼ ë‚´ê¸°ê¹Œì§€ëŠ” ì‹œê°„ì´ ì¢€ ê±¸ë¦¬ë©°, ì €í¬ëŠ” ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì— ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì €í¬ì—ê²Œ ì–´ëŠ ì •ë„ í™•ì‹ ì„ ì£¼ëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ ì •ë§ í¥ë¯¸ë¡œìš´ ì¸¡ë©´ì€ í˜„ì¬ê¹Œì§€ ì €í¬ê°€ ì§ì ‘ ì†Œë¹„ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ë§ˆì¼€íŒ…ì´ë‚˜ ì €í¬ê°€ ì§ì ‘ í›„ì›í•˜ëŠ” ì–´ë–¤ í™œë™ë„ í•˜ì§€ ì•Šì•˜ë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We've seen a tremendous amount being done organically in terms of social media posts by surgeons, press coverage, these types of things. Speaker 4: We have some very exciting programs coming in that. And so as we start to lean into that a bit more, I think there's some, there's some positive aspects you'll see developed from that as well. Speaker 1: Okay. So you didn't quite answer the question. What makes what makes it go above and what makes it go below? Speaker 4: At this point, what makes it go below is the things that we probably don't know. Right? It's it's the unknown around that.</td><td>ì™¸ê³¼ì˜ë“¤ì˜ ì†Œì…œë¯¸ë””ì–´ ê²Œì‹œë¬¼, ì–¸ë¡  ë³´ë„ ë“±ì„ í†µí•´ ìœ ê¸°ì ìœ¼ë¡œ ì—„ì²­ë‚œ í™œë™ì´ ì´ë£¨ì–´ì§€ê³  ìˆëŠ” ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ì´ì™€ ê´€ë ¨í•´ì„œ ë§¤ìš° í¥ë¯¸ë¡œìš´ í”„ë¡œê·¸ë¨ë“¤ì´ ì¤€ë¹„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ì— ì¢€ ë” ì§‘ì¤‘í•˜ê¸° ì‹œì‘í•˜ë©´ì„œ, ì´ë¡œë¶€í„° ê¸ì •ì ì¸ ì¸¡ë©´ë“¤ì´ ë°œì „ë˜ëŠ” ê²ƒì„ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì§ˆë¬¸ì— ì •í™•íˆ ë‹µë³€í•´ ì£¼ì‹œì§€ ì•Šìœ¼ì…¨ë„¤ìš”. ë¬´ì—‡ì´ ìƒí–¥ ìš”ì¸ì´ê³  ë¬´ì—‡ì´ í•˜í–¥ ìš”ì¸ì¸ê°€ìš”?<br><br>ë°œí‘œì 4: í˜„ì‹œì ì—ì„œ í•˜í–¥ ìš”ì¸ì´ ë˜ëŠ” ê²ƒì€ ì•„ë§ˆë„ ì €í¬ê°€ ì•Œì§€ ëª»í•˜ëŠ” ë¶€ë¶„ë“¤ì¼ ê²ƒì…ë‹ˆë‹¤. ë§ì£ ? ê·¸ ë¶€ë¶„ì— ëŒ€í•œ ë¶ˆí™•ì‹¤ì„±ì´ë¼ê³  í•  ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So far in the first four months, you know, as as Pete and JJ mentioned, you know, it's exceeded our expectations. You know, the demand is there. Speaker 4: We haven't seen a really strong response from the competitors yet, but we don't take them for granted. And so it's early. We're we're tracking it, and so far, everything is good. So we have a lot of confidence in where we are. What what would drag us down is something that I think we we simply don't know at this point. Speaker 4: And And what takes us above is the momentum continues that that the adoption, that that the interest, that the surgeon community just continues to embrace the technology.</td><td>ì§€ê¸ˆê¹Œì§€ ì²« 4ê°œì›” ë™ì•ˆ, Peteì™€ JJê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì €í¬ ê¸°ëŒ€ì¹˜ë¥¼ ë›°ì–´ë„˜ì—ˆìŠµë‹ˆë‹¤. ìˆ˜ìš”ê°€ í™•ì‹¤íˆ ìˆìŠµë‹ˆë‹¤.<br><br>**í™”ì 4:** ê²½ìŸì‚¬ë“¤ë¡œë¶€í„° ì•„ì§ ê°•ë ¥í•œ ëŒ€ì‘ì„ ë³´ì§€ëŠ” ëª»í–ˆì§€ë§Œ, ê·¸ë“¤ì„ ë‹¹ì—°í•˜ê²Œ ì—¬ê¸°ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì…ë‹ˆë‹¤. ì €í¬ê°€ ì¶”ì í•˜ê³  ìˆìœ¼ë©°, ì§€ê¸ˆê¹Œì§€ëŠ” ëª¨ë“  ê²ƒì´ ìˆœì¡°ë¡­ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í˜„ì¬ ì €í¬ ìœ„ì¹˜ì— ëŒ€í•´ ìƒë‹¹í•œ í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ë¥¼ ëŒì–´ë‚´ë¦´ ìˆ˜ ìˆëŠ” ìš”ì¸ì€ í˜„ ì‹œì ì—ì„œ ì €í¬ê°€ ë‹¨ìˆœíˆ ì•Œ ìˆ˜ ì—†ëŠ” ê²ƒë“¤ì…ë‹ˆë‹¤.<br><br>**í™”ì 4:** ê·¸ë¦¬ê³  ì €í¬ë¥¼ ë” ë†’ì´ ëŒì–´ì˜¬ë¦´ ìˆ˜ ìˆëŠ” ê²ƒì€ ì´ ëª¨ë©˜í…€ì´ ì§€ì†ë˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì¦‰, ë„ì…ë¥ ì´, ê´€ì‹¬ì´, ì™¸ê³¼ì˜ì‚¬ ì»¤ë®¤ë‹ˆí‹°ê°€ ì´ ê¸°ìˆ ì„ ê³„ì†í•´ì„œ ë°›ì•„ë“¤ì´ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And then some of these things we're we're doing and we noted yesterday, we have this interesting campaign we're gonna be kicking off here very soon with an A list celebrity. First time in, I think, the breast augmentation arena that a celebrity of that stature has been willing to talk about her experience with breast augmentation and specifically talk about the brand that she chose and why she chose it. And so I think that's gonna be a very powerful message for us coming here in the next few weeks. And so we have a lot of good things coming. Speaker 1: And you can share her name?</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” ì´ëŸ¬í•œ í™œë™ë“¤ ì¤‘ ì¼ë¶€ëŠ” ì–´ì œ ì–¸ê¸‰í–ˆë“¯ì´, ê³§ Aê¸‰ ìœ ëª…ì¸ê³¼ í•¨ê»˜ ì‹œì‘í•  ë§¤ìš° í¥ë¯¸ë¡œìš´ ìº í˜ì¸ì´ ìˆìŠµë‹ˆë‹¤. ì œ ìƒê°ì—ëŠ” ìœ ë°©í™•ëŒ€ìˆ  ë¶„ì•¼ì—ì„œ ê·¸ ì •ë„ ìœ„ìƒì˜ ìœ ëª…ì¸ì´ ìì‹ ì˜ ìœ ë°©í™•ëŒ€ìˆ  ê²½í—˜ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³ , íŠ¹íˆ ìì‹ ì´ ì„ íƒí•œ ë¸Œëœë“œì™€ ê·¸ ì„ íƒ ì´ìœ ì— ëŒ€í•´ êµ¬ì²´ì ìœ¼ë¡œ ì–¸ê¸‰í•˜ê¸°ë¡œ í•œ ê²ƒì€ ì²˜ìŒì¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì•ìœ¼ë¡œ ëª‡ ì£¼ ë‚´ì— ìš°ë¦¬ì—ê²Œ ë§¤ìš° ê°•ë ¥í•œ ë©”ì‹œì§€ê°€ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ì—ê²ŒëŠ” ë§ì€ ì¢‹ì€ ì¼ë“¤ì´ ê¸°ë‹¤ë¦¬ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ê·¸ ë¶„ì˜ ì´ë¦„ì„ ê³µê°œí•  ìˆ˜ ìˆë‚˜ìš”?</td></tr>
<tr><td>Speaker 3: Not at this point, but I think, people will be pleased, especially because, when we think about what what Motiva is doing, it's in a, you know, technology starved environment bringing the new options. And I think, part of these celebrities' journey into this was supported by our technology. And and, you know, people don't understand perhaps yet how important it is to women for instance to put the implant above the muscle, not sacrificing the pectoralis muscle, especially if you're physically very active. It's a big thing. And the other part is the move towards breast tissue preservation. Speaker 3: Breast tissue preservation starts at the cellular level.</td><td>í™”ì 3: í˜„ì¬ë¡œì„œëŠ” ê·¸ë ‡ì§€ ì•ŠìŠµë‹ˆë‹¤ë§Œ, ì‚¬ëŒë“¤ì´ ë§Œì¡±í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. íŠ¹íˆ Motivaê°€ í•˜ê³  ìˆëŠ” ì¼ì„ ìƒê°í•´ë³´ë©´, ê¸°ìˆ ì´ ë¶€ì¡±í•œ í™˜ê²½ì—ì„œ ìƒˆë¡œìš´ ì˜µì…˜ì„ ì œê³µí•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ìœ ëª…ì¸ë“¤ì´ ì´ ë¶„ì•¼ì— ì§„ì¶œí•˜ê²Œ ëœ ê²ƒë„ ë¶€ë¶„ì ìœ¼ë¡œëŠ” ì €í¬ ê¸°ìˆ ì˜ ì§€ì›ì´ ìˆì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì•„ì§ ì‚¬ëŒë“¤ì´ ì´í•´í•˜ì§€ ëª»í•˜ê³  ìˆëŠ” ë¶€ë¶„ì´ ìˆëŠ”ë°, íŠ¹íˆ ì—¬ì„±ë“¤ì—ê²Œ ìˆì–´ì„œ ëŒ€í‰ê·¼ì„ í¬ìƒí•˜ì§€ ì•Šê³  ê·¼ìœ¡ ìœ„ì— ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•˜ëŠ” ê²ƒì´ ì–¼ë§ˆë‚˜ ì¤‘ìš”í•œì§€ ë§ì…ë‹ˆë‹¤. íŠ¹íˆ ì‹ ì²´ í™œë™ì´ ë§¤ìš° í™œë°œí•œ ê²½ìš°ì—ëŠ” ë”ìš± ì¤‘ìš”í•œ ë¬¸ì œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë˜ ë‹¤ë¥¸ ë¶€ë¶„ì€ ìœ ë°© ì¡°ì§ ë³´ì¡´ìœ¼ë¡œì˜ ì „í™˜ì…ë‹ˆë‹¤.<br><br>í™”ì 3: ìœ ë°© ì¡°ì§ ë³´ì¡´ì€ ì„¸í¬ ìˆ˜ì¤€ì—ì„œ ì‹œì‘ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Our surface has been proven to be the least inflammatory surface of any implant in the market. So these are the things that matter. People these days, they talk about a lot about inflammation in their health checks. So having a low inflammatory implant is a big thing. Speaker 3: And, you know, as as the story evolves and some of the communication that we see from the plastic surgeons on, you know, different social media is about these things that are so important to women. Excellent. Speaker 1: There was a question last night that I thought was really interesting. Where are you taking share from?</td><td>ìš°ë¦¬ì˜ í‘œë©´ì€ ì‹œì¥ì— ìˆëŠ” ëª¨ë“  ì„í”Œë€íŠ¸ ì¤‘ì—ì„œ ê°€ì¥ ì—¼ì¦ ë°˜ì‘ì´ ì ì€ í‘œë©´ì„ì´ ì…ì¦ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ° ê²ƒë“¤ì´ ì¤‘ìš”í•œ ìš”ì†Œë“¤ì…ë‹ˆë‹¤. ìš”ì¦˜ ì‚¬ëŒë“¤ì€ ê±´ê°• ê²€ì§„ì—ì„œ ì—¼ì¦ì— ëŒ€í•´ ë§ì´ ì´ì•¼ê¸°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì—¼ì¦ ë°˜ì‘ì´ ë‚®ì€ ì„í”Œë€íŠ¸ë¥¼ ê°–ëŠ” ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•œ ì¼ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ê·¸ë¦¬ê³  ì•„ì‹œë‹¤ì‹œí”¼, ì´ì•¼ê¸°ê°€ ì „ê°œë˜ë©´ì„œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì´ ë‹¤ì–‘í•œ ì†Œì…œ ë¯¸ë””ì–´ë¥¼ í†µí•´ ì „ë‹¬í•˜ëŠ” ì¼ë¶€ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ì„ ë³´ë©´, ì—¬ì„±ë“¤ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ ì´ëŸ° ê²ƒë“¤ì— ëŒ€í•œ ë‚´ìš©ì…ë‹ˆë‹¤. í›Œë¥­í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì–´ì ¯ë°¤ì— ì •ë§ í¥ë¯¸ë¡œì› ë‹¤ê³  ìƒê°í•œ ì§ˆë¬¸ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ì–´ë””ì„œ ì‹œì¥ ì ìœ ìœ¨ì„ ê°€ì ¸ì˜¤ê³  ê³„ì‹ ê°€ìš”?</td></tr>
<tr><td>Speaker 3: Well, at at this point, it's it's early, you know, so we can't specifically say one or the other. But definitely, I think, you know, there's a there's a clear market leader in The United States. It's, you know, Allergan Aesthetics in, in in breast implant space. So a lot of it comes by definition from them because of their share that they have right now. But eventually, I think it's it's it's across the board. Speaker 3: It's every single surgeon who's interested in attracting more patients through the safety and the new options from our technology. Speaker 1: Asking the question slightly different way. Does this accelerate market growth?</td><td>**ë°œí‘œì 3:** ìŒ, í˜„ì¬ë¡œì„œëŠ” ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì´ê¸° ë•Œë¬¸ì— êµ¬ì²´ì ìœ¼ë¡œ ì–´ëŠ ìª½ì´ë¼ê³  ëª…í™•íˆ ë§ì”€ë“œë¦´ ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë¶„ëª…íˆ ë¯¸êµ­ì—ì„œëŠ” ëª…í™•í•œ ì‹œì¥ ë¦¬ë”ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìœ ë°© ì„í”Œë€íŠ¸ ë¶„ì•¼ì—ì„œëŠ” ì•ŒëŸ¬ê°„ ì—ìŠ¤í…Œí‹±ìŠ¤(Allergan Aesthetics)ê°€ ê·¸ ì£¼ì¸ê³µì´ì£ . ë”°ë¼ì„œ í˜„ì¬ ê·¸ë“¤ì´ ë³´ìœ í•œ ì‹œì¥ ì ìœ ìœ¨ì„ ê³ ë ¤í•  ë•Œ, ì •ì˜ìƒ ìƒë‹¹ ë¶€ë¶„ì´ ê·¸ë“¤ë¡œë¶€í„° ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê¶ê·¹ì ìœ¼ë¡œëŠ” ì „ë°˜ì ì¸ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>**ë°œí‘œì 3:** ìš°ë¦¬ ê¸°ìˆ ì˜ ì•ˆì „ì„±ê³¼ ìƒˆë¡œìš´ ì˜µì…˜ì„ í†µí•´ ë” ë§ì€ í™˜ìë¥¼ ìœ ì¹˜í•˜ëŠ” ë° ê´€ì‹¬ì´ ìˆëŠ” ëª¨ë“  ì™¸ê³¼ì˜ì‚¬ë“¤ì´ ëŒ€ìƒì…ë‹ˆë‹¤.<br><br>**ë°œí‘œì 1:** ì§ˆë¬¸ì„ ì¡°ê¸ˆ ë‹¤ë¥´ê²Œ í•´ë³´ê² ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì‹œì¥ ì„±ì¥ì„ ê°€ì†í™”ì‹œí‚¤ë‚˜ìš”?</td></tr>
<tr><td>You you already commented on a halo effect outside The United States. So do you think this accelerates, US market growth? Speaker 3: It's a potential accelerator for US market growth. Speaker 1: Okay. Well, it can't be a decelerator. Alright. That's cool. Anything else we should talk about as it comes to The US market? Speaker 1: You gave some great stats last night. Speaker 3: Well, I I think one of the important things as well is what's coming next. And I think we gave very good pipeline and how that's going to develop over the next few years. You know, our three year data from the recon cohorts is coming in, you know, at the end of the summer.</td><td>ì´ë¯¸ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œì˜ í›„ê´‘ íš¨ê³¼ì— ëŒ€í•´ ì–¸ê¸‰í•´ ì£¼ì…¨ëŠ”ë°ìš”. ì´ê²ƒì´ ë¯¸êµ­ ì‹œì¥ ì„±ì¥ì„ ê°€ì†í™”í•  ê²ƒì´ë¼ê³  ë³´ì‹œë‚˜ìš”?<br><br>ë°œí‘œì 3: ë¯¸êµ­ ì‹œì¥ ì„±ì¥ì˜ ì ì¬ì  ê°€ì† ìš”ì¸ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì•Œê² ìŠµë‹ˆë‹¤. ì„±ì¥ ë‘”í™” ìš”ì¸ì€ ë  ìˆ˜ ì—†ê² ì£ . ì¢‹ë„¤ìš”. ë¯¸êµ­ ì‹œì¥ê³¼ ê´€ë ¨í•´ì„œ ë‹¤ë¥¸ ë…¼ì˜í•  ì‚¬í•­ì´ ìˆì„ê¹Œìš”?<br><br>ë°œí‘œì 1: ì–´ì ¯ë°¤ì— í›Œë¥­í•œ í†µê³„ ìë£Œë“¤ì„ ì œì‹œí•´ ì£¼ì…¨ëŠ”ë°ìš”.<br><br>ë°œí‘œì 3: ìŒ, ì œê°€ ìƒê°í•˜ê¸°ì— ì¤‘ìš”í•œ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ì•ìœ¼ë¡œ ë‹¤ê°€ì˜¬ ê²ƒë“¤ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í–¥í›„ ëª‡ ë…„ê°„ ì–´ë–»ê²Œ ë°œì „í• ì§€ì— ëŒ€í•œ ë§¤ìš° ì¢‹ì€ íŒŒì´í”„ë¼ì¸ì„ ì œì‹œí–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ì¬ê±´(recon) ì½”í˜¸íŠ¸ì˜ 3ë…„ ë°ì´í„°ê°€ ì˜¬ì—¬ë¦„ ë§ì— ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So, you know, later in the second half, we'll be, giving the supplement to the FDA, which brings about a potential launch into breast reconstruction in 2026. Breast reconstruction is a very important market, not only because of the amount of breast reconstructions that are<br><br>undertaken in The United States, but also the price point that these are recognized. Speaker 3: So that's particularly important. Also, we have this amazing, you know, tissue expander technology that is unique because it allows for MRIs during the expansion process. And being able to focus both technologies into breast recon brings about, you know, a lot of efficiencies and potential growth.</td><td>ë”°ë¼ì„œ í•˜ë°˜ê¸°ì— FDAì— ë³´ì™„ ìë£Œë¥¼ ì œì¶œí•  ì˜ˆì •ì´ë©°, ì´ë¥¼ í†µí•´ 2026ë…„ ìœ ë°©ì¬ê±´ ì‹œì¥ ì§„ì¶œ ê°€ëŠ¥ì„±ì„ ì—´ì–´ë†“ê³  ìˆìŠµë‹ˆë‹¤. ìœ ë°©ì¬ê±´ì€ ë§¤ìš° ì¤‘ìš”í•œ ì‹œì¥ì…ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ì‹œí–‰ë˜ëŠ” ìœ ë°©ì¬ê±´ ìˆ˜ìˆ ì˜ ê·œëª¨ë¿ë§Œ ì•„ë‹ˆë¼ ì´ëŸ¬í•œ ì‹œìˆ ì´ ì¸ì •ë°›ëŠ” ê°€ê²©ëŒ€ ì¸¡ë©´ì—ì„œë„ ê·¸ë ‡ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì´ëŠ” íŠ¹íˆ ì¤‘ìš”í•©ë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” í™•ì¥ ê³¼ì • ì¤‘ì—ë„ MRI ì´¬ì˜ì´ ê°€ëŠ¥í•œ ë…íŠ¹í•œ ì¡°ì§ í™•ì¥ê¸° ê¸°ìˆ ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë‘ ê¸°ìˆ ì„ ìœ ë°©ì¬ê±´ì— ì§‘ì¤‘í•¨ìœ¼ë¡œì¨ ë§ì€ íš¨ìœ¨ì„±ê³¼ ì„±ì¥ ì ì¬ë ¥ì„ ê°€ì ¸ì˜¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But beyond breast recon, we have, you know, our, you know, Preserve, which is our latest launch of our minimally invasive platform, and eventually the Ergonomics two, platform, which brings about the possibility of Mia, which is the, you know, minimally invasive breast harmonization suite that we have now in about 20 countries worldwide. Speaker 1: Okay. A lot of questions to unpack there. I had not heard, and maybe this is my fault, about Proserve and somewhat recently. How is that differentiated from, how should we think about that market positioning? Speaker 3: I I think that's a really important thing because, in a way, Crestorvey was born from the Mia experience. Okay.</td><td>í•˜ì§€ë§Œ ìœ ë°© ì¬ê±´ìˆ ì„ ë„˜ì–´ì„œ, ì €í¬ì—ê²ŒëŠ” ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì˜ ìµœì‹  ì¶œì‹œ ì œí’ˆì¸ Preserveê°€ ìˆê³ , ê¶ê·¹ì ìœ¼ë¡œëŠ” Ergonomics 2 í”Œë«í¼ì´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ì „ ì„¸ê³„ ì•½ 20ê°œêµ­ì—ì„œ ìš´ì˜ ì¤‘ì¸ ìµœì†Œì¹¨ìŠµ ìœ ë°© ì¡°í™” ì œí’ˆêµ°ì¸ Miaì˜ ê°€ëŠ¥ì„±ì„ ì—´ì–´ì¤ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì•Œê² ìŠµë‹ˆë‹¤. í’€ì–´ì•¼ í•  ì§ˆë¬¸ì´ ë§ë„¤ìš”. Proserveì— ëŒ€í•´ì„œëŠ” ë“¤ì–´ë³¸ ì ì´ ì—†ëŠ”ë°, ì•„ë§ˆ ì œê°€ ë†“ì¹œ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ìµœê·¼ì— ë‚˜ì˜¨ ê²ƒ ê°™ì€ë°ìš”. ì´ê²ƒì´ ì–´ë–»ê²Œ ì°¨ë³„í™”ë˜ëŠ”ì§€, ì‹œì¥ í¬ì§€ì…”ë‹ì„ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”?<br><br>ë°œí‘œì 3: ì •ë§ ì¤‘ìš”í•œ ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì–´ë–¤ ë©´ì—ì„œ CrestorveyëŠ” Mia ê²½í—˜ì—ì„œ íƒ„ìƒí–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 1: So<br><br><br>Speaker 3: when we created the minimally invasive platform, you know, we first created Mia, which is a market expansion play. Really, what you are attracting are, you know, mostly women who are, you know, currently using padded bras, push up bras, or other compensatory behaviors to look at an option that they never thought about because they're not interested in breast augmentation and already early on, you know, the launch of Mia, we have seen that, you know, more than forty percent of women getting Mia were not interested at all in breast augmentation.</td><td>ë°œí‘œì 3: ì €í¬ê°€ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ê°œë°œí–ˆì„ ë•Œ, ë¨¼ì € Miaë¥¼ ì¶œì‹œí–ˆëŠ”ë°, ì´ëŠ” ì‹œì¥ í™•ì¥ ì „ëµì´ì—ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì €í¬ê°€ íƒ€ê²Ÿìœ¼ë¡œ í•˜ëŠ” ê³ ê°ì¸µì€ ì£¼ë¡œ íŒ¨ë“œ ë¸Œë¼ë‚˜ í‘¸ì‹œì—… ë¸Œë¼, ë˜ëŠ” ë‹¤ë¥¸ ë³´ì • ë°©ë²•ë“¤ì„ ì‚¬ìš©í•˜ê³  ìˆëŠ” ì—¬ì„±ë“¤ë¡œ, ìœ ë°©í™•ëŒ€ìˆ ì—ëŠ” ê´€ì‹¬ì´ ì—†ê¸° ë•Œë¬¸ì— ì´ì „ì—ëŠ” ì „í˜€ ê³ ë ¤í•´ë³´ì§€ ì•Šì•˜ë˜ ì˜µì…˜ì„ ì œê³µí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. Mia ì¶œì‹œ ì´ˆê¸°ë¶€í„° ì´ë¯¸ í™•ì¸í•  ìˆ˜ ìˆì—ˆë˜ ê²ƒì€, Mia ì‹œìˆ ì„ ë°›ëŠ” ì—¬ì„±ì˜ 40% ì´ìƒì´ ìœ ë°©í™•ëŒ€ìˆ ì—ëŠ” ì „í˜€ ê´€ì‹¬ì´ ì—†ì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>CRISERVE basically uses that experience and brings breast tissue preservation and a less invasive procedure, not a fully minimally invasive procedure, less invasive<br><br>procedure into the day to day of the plastic surgeon. So there we are talking about breast augmentations of more than two cups up. You're talking about, you know, augmentation mastopexis. Speaker 3: Mastopexis are like the surgical lifts, which is, you know, happens often as a mommy makeover. And, you know, Preserve allows for us to be able to deescalate therapeutically those procedures because you are making the procedure less invasive. And that's the day to day of the plastic surgeon.</td><td>CRISERVEëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ê·¸ëŸ¬í•œ ê²½í—˜ì„ í™œìš©í•˜ì—¬ ìœ ë°© ì¡°ì§ ë³´ì¡´ê³¼ ëœ ì¹¨ìŠµì ì¸ ì‹œìˆ ì„ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ì˜ ì¼ìƒ ì§„ë£Œì— ë„ì…í•©ë‹ˆë‹¤. ì™„ì „íˆ ìµœì†Œì¹¨ìŠµì ì¸ ì‹œìˆ ì€ ì•„ë‹ˆì§€ë§Œ, ëœ ì¹¨ìŠµì ì¸ ì‹œìˆ ì„ ì œê³µí•©ë‹ˆë‹¤.<br><br>ì—¬ê¸°ì„œ ìš°ë¦¬ê°€ ë§í•˜ëŠ” ê²ƒì€ 2ì»µ ì´ìƒì˜ ìœ ë°© í™•ëŒ€ìˆ ì…ë‹ˆë‹¤. í™•ëŒ€ ìœ ë°©ê³ ì •ìˆ ì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë¦¬ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í™”ì 3: ìœ ë°©ê³ ì •ìˆ ì€ ì™¸ê³¼ì  ë¦¬í”„íŒ…ê³¼ ê°™ì€ ê²ƒìœ¼ë¡œ, í”íˆ ë§˜ë¯¸ ë©”ì´í¬ì˜¤ë²„ì˜ ì¼í™˜ìœ¼ë¡œ ì‹œí–‰ë©ë‹ˆë‹¤. Preserveë¥¼ í†µí•´ ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ì‹œìˆ ë“¤ì„ ì¹˜ë£Œì ìœ¼ë¡œ ì™„í™”ì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì‹œìˆ ì„ ëœ ì¹¨ìŠµì ìœ¼ë¡œ ë§Œë“¤ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ì˜ ì¼ìƒ ì§„ë£Œì…ë‹ˆë‹¤.</td></tr>
<tr><td>So being able to bring them this is going to help, you know, the adoption and also the move into the world of minimally invasive as<br><br>Speaker 1: Okay. So so just to simplify, you have, you have preservant you have MEA, which is maybe an outpatient procedure, maybe, one cup size, two cup size. You graduate to to three cup sizes, I think you said, and then you have a full implant. Is that the right way to think about the portfolio? Speaker 3: So the way to think about it is within the minimally invasive platform, the most premium offering is Miele. Okay. You know? And then Preserve is more for, like, the grand majority of plastic surgeons.</td><td>ê·¸ë˜ì„œ ì´ë“¤ì—ê²Œ ì´ê²ƒì„ ì œê³µí•  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì€ ë„ì…ì„ ì´‰ì§„í•˜ê³  ìµœì†Œì¹¨ìŠµ ì„¸ê³„ë¡œì˜ ì „í™˜ì—ë„ ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>**ë°œì–¸ì 1**: ì¢‹ìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë©´ ë‹¨ìˆœí™”í•´ì„œ ë§ì”€ë“œë¦¬ë©´, í”„ë¦¬ì €ë²ˆíŠ¸ê°€ ìˆê³  MEAê°€ ìˆëŠ”ë°, ì´ëŠ” ì•„ë§ˆë„ ì™¸ë˜í™˜ì ì‹œìˆ ë¡œ ì»µ ì‚¬ì´ì¦ˆ 1ë‹¨ê³„, 2ë‹¨ê³„ ì •ë„ ì¦ê°€ì‹œí‚¤ëŠ” ê²ƒì´ê³ ìš”. 3ë‹¨ê³„ê¹Œì§€ ì˜¬ë¼ê°„ë‹¤ê³  ë§ì”€í•˜ì…¨ë˜ ê²ƒ ê°™ì€ë°, ê·¸ ë‹¤ìŒì—ëŠ” ì™„ì „í•œ ì„í”Œë€íŠ¸ê°€ ìˆëŠ” ê±°ì£ ? í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì´ë ‡ê²Œ ì´í•´í•˜ëŠ” ê²ƒì´ ë§ë‚˜ìš”?<br><br>**ë°œì–¸ì 3**: ì´ë ‡ê²Œ ìƒê°í•˜ì‹œë©´ ë©ë‹ˆë‹¤. ìµœì†Œì¹¨ìŠµ í”Œë«í¼ ë‚´ì—ì„œ ê°€ì¥ í”„ë¦¬ë¯¸ì—„ ì œí’ˆì€ ë¯¸ì—˜ë ˆì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í”„ë¦¬ì €ë¸ŒëŠ” ëŒ€ë‹¤ìˆ˜ì˜ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì„ ìœ„í•œ ì œí’ˆì´ë¼ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>And that's why, you know, when you think about over time, you know, we will have a group of surgeon that goes into minimally invasive breast tissue preservation through the Preserve brand and a group of surgeons that are more boutique, more premium who will go through MIA. Speaker 3: So both of them create growth, you know, and in the case of MIA, market expansion. Speaker 1: Okay. And there are tools that go along with both of these MIS opportunities. Exactly. And the tools get FDA approved separately? Speaker 3: It's a separate approval from the implants. Speaker 1: Okay. From a sales and marketing perspective, the tools and the implant are sold as part of a box?</td><td>ê·¸ë˜ì„œ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ, ìµœì†Œì¹¨ìŠµ ìœ ë°©ì¡°ì§ ë³´ì¡´ìˆ ì„ ì‹œí–‰í•˜ëŠ” ì™¸ê³¼ì˜ì‚¬ ê·¸ë£¹ì€ Preserve ë¸Œëœë“œë¥¼ í†µí•´, ê·¸ë¦¬ê³  ë” ë¶€í‹°í¬í•˜ê³  í”„ë¦¬ë¯¸ì—„ì„ ì¶”êµ¬í•˜ëŠ” ì™¸ê³¼ì˜ì‚¬ ê·¸ë£¹ì€ MIAë¥¼ í†µí•´ ì§„í–‰í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë‘ ì œí’ˆ ëª¨ë‘ ì„±ì¥ì„ ì°½ì¶œí•˜ë©°, MIAì˜ ê²½ìš°ì—ëŠ” ì‹œì¥ í™•ì¥ì„ ê°€ì ¸ì˜µë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ë‘ MIS ê¸°íšŒì™€ í•¨ê»˜ ì‚¬ìš©ë˜ëŠ” ë„êµ¬ë“¤ì´ ìˆëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ë§ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë„êµ¬ë“¤ì€ FDA ìŠ¹ì¸ì„ ë³„ë„ë¡œ ë°›ë‚˜ìš”?<br><br>ë°œí‘œì 3: ì„í”Œë€íŠ¸ì™€ëŠ” ë³„ë„ì˜ ìŠ¹ì¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì•Œê² ìŠµë‹ˆë‹¤. ì˜ì—… ë° ë§ˆì¼€íŒ… ê´€ì ì—ì„œ, ë„êµ¬ì™€ ì„í”Œë€íŠ¸ëŠ” í•˜ë‚˜ì˜ íŒ¨í‚¤ì§€ë¡œ íŒë§¤ë˜ë‚˜ìš”?</td></tr>
<tr><td>Speaker 3: They're part of a system. They're not packed in the same box, but they're part of a system because they're intended to be used together with the techniques that we have put forward. Speaker 1: You have really cool packaging. That's why I was asking. Speaker 3: Thank you. Speaker 1: Okay. Where to go from here? I think we just went into a whole MIS direction I had was fully planning on. Preserve was launched in Brazil. It was the first country of the rollout. Speaker 1: Can you sort of think about where it goes next? Speaker 3: Yeah.</td><td>í™”ì 3: ì´ë“¤ì€ ì‹œìŠ¤í…œì˜ ì¼ë¶€ì…ë‹ˆë‹¤. ê°™ì€ ë°•ìŠ¤ì— í¬ì¥ë˜ì§€ëŠ” ì•Šì§€ë§Œ, ì €í¬ê°€ ì œì‹œí•œ ê¸°ìˆ ë“¤ê³¼ í•¨ê»˜ ì‚¬ìš©ë˜ë„ë¡ ì„¤ê³„ë˜ì—ˆê¸° ë•Œë¬¸ì— ì‹œìŠ¤í…œì˜ ì¼ë¶€ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>í™”ì 1: ì •ë§ ë©‹ì§„ í¬ì¥ì´ë„¤ìš”. ê·¸ë˜ì„œ ì§ˆë¬¸ë“œë¦° ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 3: ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>í™”ì 1: ì¢‹ìŠµë‹ˆë‹¤. ì´ì œ ì–´ë””ë¡œ ê°€ì•¼ í• ê¹Œìš”? ì œê°€ ì™„ì „íˆ ê³„íší–ˆë˜ MIS ë°©í–¥ìœ¼ë¡œ ë“¤ì–´ê°„ ê²ƒ ê°™ë„¤ìš”. PreserveëŠ” ë¸Œë¼ì§ˆì—ì„œ ì¶œì‹œë˜ì—ˆê³ , ì´ëŠ” ë¡¤ì•„ì›ƒì˜ ì²« ë²ˆì§¸ êµ­ê°€ì˜€ìŠµë‹ˆë‹¤.<br><br>í™”ì 1: ë‹¤ìŒì—ëŠ” ì–´ë””ë¡œ í™•ì¥ë ì§€ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œë‚˜ìš”?<br><br>í™”ì 3: ë„¤.</td></tr>
<tr><td>And actually, we we talked about it in, you know, at at the JPMorgan conference earlier this year is that, you know, the plan is to then bring it to Europe and, of course, move it worldwide. So, you know, you're gonna see a lot of launches of Preserve throughout this year, and, you know, the level of excitement, from the plastic surgeons is tremendous because it simplifies their, you know, their work. It makes each one of these procedures simpler for them and their recovery faster for the patient and, hence, the excitement from them.</td><td>ê·¸ë¦¬ê³  ì‹¤ì œë¡œ ì €í¬ê°€ ì˜¬í•´ ì´ˆ JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ê³„íšì€ ì´ë¥¼ ìœ ëŸ½ìœ¼ë¡œ ê°€ì ¸ì˜¨ ë‹¤ìŒ ì „ ì„¸ê³„ë¡œ í™•ì¥í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì˜¬í•´ Preserveì˜ ì¶œì‹œë¥¼ ë§ì´ ë³´ê²Œ ë˜ì‹¤ ê²ƒì´ê³ , ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì˜ í¥ë¯¸ ìˆ˜ì¤€ì€ ì—„ì²­ë‚©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ ì œí’ˆì´ ê·¸ë“¤ì˜ ì—…ë¬´ë¥¼ ë‹¨ìˆœí™”ì‹œì¼œ ì£¼ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê°ê°ì˜ ì‹œìˆ ì„ ë” ê°„ë‹¨í•˜ê²Œ ë§Œë“¤ì–´ ì£¼ê³  í™˜ìì˜ íšŒë³µì„ ë” ë¹ ë¥´ê²Œ í•´ì£¼ë¯€ë¡œ, ê·¸ë“¤ë¡œë¶€í„° í° ê´€ì‹¬ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 1: And then to backtrack on Mia, which can you remind us which geographies have already been launched in and the timing to bring that to The<br><br>Speaker 3: US. So, it's been launched in Japan and Europe, and we're going to continue expanding into more countries this year. We have over 60 clinics. We talked about more than<br><br>doubling the amount of clinics this year, and cities in which you have those clinics for MIA.</td><td>**ë°œí‘œì 1:** ê·¸ë¦¬ê³  Miaì— ëŒ€í•´ ë‹¤ì‹œ ëŒì•„ê°€ì„œ, ì´ë¯¸ ì¶œì‹œëœ ì§€ì—­ë“¤ê³¼ ë¯¸êµ­ ì¶œì‹œ ì‹œê¸°ì— ëŒ€í•´ ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?<br><br>**ë°œí‘œì 3:** ì¼ë³¸ê³¼ ìœ ëŸ½ì—ì„œ ì¶œì‹œë˜ì—ˆìœ¼ë©°, ì˜¬í•´ ë” ë§ì€ êµ­ê°€ë¡œ í™•ì¥ì„ ê³„ì†í•  ì˜ˆì •ì…ë‹ˆë‹¤. í˜„ì¬ 60ê°œ ì´ìƒì˜ í´ë¦¬ë‹‰ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ MIA í´ë¦¬ë‹‰ ìˆ˜ë¥¼ ë‘ ë°° ì´ìƒ ëŠ˜ë¦´ ê²ƒì´ë¼ê³  ë§ì”€ë“œë ¸ëŠ”ë°, ì´ëŠ” í•´ë‹¹ í´ë¦¬ë‹‰ë“¤ì´ ìœ„ì¹˜í•œ ë„ì‹œë“¤ë„ í¬í•¨í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>For The US, you know, we're in that in that cadence of supplements eventually going to propose to the FDA the supplement of the Ergonomix II platform, which is necessary for Mia because it's which allows for these implants to be injected, and that is necessary for the minimally invasive procedure to take place. Speaker 1: Okay. Speaker 3: Good. So we're not we're not sticking to a particular one. I think it's more like you think about it not as a 2026, but potentially more like, you know, beyond that. Also important to understand is that, you know, with the cadence of launches that we have, it's gonna be pretty packed.</td><td>ë¯¸êµ­ì˜ ê²½ìš°, ì €í¬ëŠ” í˜„ì¬ FDAì— Ergonomix II í”Œë«í¼ì— ëŒ€í•œ ë³´ì™„ ìë£Œë¥¼ ì œì¶œí•  ì˜ˆì •ì¸ ë‹¨ê³„ì— ìˆìŠµë‹ˆë‹¤. ì´ëŠ” Miaì— í•„ìˆ˜ì ì¸ í”Œë«í¼ìœ¼ë¡œ, ì„í”Œë€íŠ¸ ì£¼ì…ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ë©° ìµœì†Œì¹¨ìŠµ ì‹œìˆ ì„ ìœ„í•´ ë°˜ë“œì‹œ í•„ìš”í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì•Œê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì¢‹ìŠµë‹ˆë‹¤. ì €í¬ëŠ” íŠ¹ì •í•œ í•˜ë‚˜ì—ë§Œ ê³ ì§‘í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. 2026ë…„ì´ë¼ê¸°ë³´ë‹¤ëŠ” ê·¸ ì´í›„ ì‹œì ìœ¼ë¡œ ìƒê°í•˜ì‹œëŠ” ê²ƒì´ ë” ì ì ˆí•  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë˜í•œ ì¤‘ìš”í•œ ì ì€ ì €í¬ê°€ ê³„íší•˜ê³  ìˆëŠ” ì¶œì‹œ ì¼ì •ë“¤ì„ ê³ ë ¤í•˜ë©´ ìƒë‹¹íˆ ë¹¡ë¹¡í•œ ìŠ¤ì¼€ì¤„ì´ ë  ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So you want to make sure that you do it in a way so that each one of these launches gets its proper time and resources. Speaker 1: Maybe describe or catch us up on ergonomics too. And what is differentiated about that and why that's important to the Mayo? Speaker 3: Ergonomics two is basically, you know, the world of the super silicones. It's this new type of arrangement of the molecules in the, in the dispersions that are necessary to make these implants. And that what allows for, you know, these extreme mechanical properties, the elongation, you know, potential of these implants so that you can actually inject them.</td><td>ë”°ë¼ì„œ ê°ê°ì˜ ì¶œì‹œê°€ ì ì ˆí•œ ì‹œê°„ê³¼ ìì›ì„ í™•ë³´í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ë°©ì‹ìœ¼ë¡œ ì§„í–‰í•´ì•¼ í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì–´ê³ ë…¸ë¯¹ìŠ¤ íˆ¬(Ergonomics 2)ì— ëŒ€í•´ì„œë„ ì„¤ëª…í•´ ì£¼ì‹œê±°ë‚˜ í˜„í™©ì„ ì•Œë ¤ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ê·¸ê²ƒì˜ ì°¨ë³„í™”ëœ ì ê³¼ ë©”ì´ìš”(Mayo)ì—ê²Œ ì™œ ì¤‘ìš”í•œì§€ ë§ì”€í•´ ì£¼ì„¸ìš”.<br><br>ë°œí‘œì 3: ì–´ê³ ë…¸ë¯¹ìŠ¤ íˆ¬ëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ìŠˆí¼ ì‹¤ë¦¬ì½˜ì˜ ì„¸ê³„ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ëŸ¬í•œ ì„í”Œë€íŠ¸ë¥¼ ì œì¡°í•˜ëŠ” ë° í•„ìš”í•œ ë¶„ì‚°ì•¡ ë‚´ ë¶„ìë“¤ì˜ ìƒˆë¡œìš´ í˜•íƒœì˜ ë°°ì—´ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì´ëŸ¬í•œ ì„í”Œë€íŠ¸ë“¤ì˜ ê·¹í•œì˜ ê¸°ê³„ì  íŠ¹ì„±, ì¦‰ ì—°ì‹ ìœ¨ ì ì¬ë ¥ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ì—¬ ì‹¤ì œë¡œ ì£¼ì…í•  ìˆ˜ ìˆê²Œ í•´ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Also, it provides a softness never seen before without creating rippling or wrinkling of the implant. And this is particularly important as well in breast reconstruction because it gives you the opportunity to really improve the quality of the breast reconstruction. Speaker 3: So it has an impact in aesthetics because it it creates that world of minimally invasive, you know, procedures are done in ten minutes without, you know, any general anesthesia. And then in breast reconstruction, absolutely, by, you know, bringing about this<br><br>concept of aesthetic breast recon. Speaker 1: Okay. One of the things you talk about is, a price premiums a premium pricing strategy.</td><td>ë˜í•œ ì„í”Œë€íŠ¸ì˜ ì£¼ë¦„ì´ë‚˜ ë¬¼ê²° í˜„ìƒì„ ì¼ìœ¼í‚¤ì§€ ì•Šìœ¼ë©´ì„œë„ ì´ì „ì—ëŠ” ë³¼ ìˆ˜ ì—†ì—ˆë˜ ë¶€ë“œëŸ¬ì›€ì„ ì œê³µí•©ë‹ˆë‹¤. ì´ëŠ” íŠ¹íˆ ìœ ë°© ì¬ê±´ìˆ ì—ì„œë„ ì¤‘ìš”í•œë°, ìœ ë°© ì¬ê±´ìˆ ì˜ í’ˆì§ˆì„ ì‹¤ì§ˆì ìœ¼ë¡œ ê°œì„ í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë¯¸ìš© ë¶„ì•¼ì—ì„œëŠ” ì „ì‹ ë§ˆì·¨ ì—†ì´ 10ë¶„ ë§Œì— ì™„ë£Œë˜ëŠ” ìµœì†Œì¹¨ìŠµ ì‹œìˆ ì˜ ì„¸ê³„ë¥¼ ì°½ì¡°í•˜ê¸° ë•Œë¬¸ì— ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìœ ë°© ì¬ê±´ìˆ ì—ì„œëŠ” í™•ì‹¤íˆ ë¯¸ìš©ì  ìœ ë°© ì¬ê±´ì´ë¼ëŠ” ê°œë…ì„ ë„ì…í•¨ìœ¼ë¡œì¨ ì ˆëŒ€ì ì¸ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì•Œê² ìŠµë‹ˆë‹¤. ê·€í•˜ê»˜ì„œ ì–¸ê¸‰í•˜ì‹  ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” í”„ë¦¬ë¯¸ì—„ ê°€ê²© ì „ëµì…ë‹ˆë‹¤.</td></tr>
<tr><td>It may be related to one product, but not broadly. How do you think about pricing your products versus competition? Speaker 3: So, you know, we never we're a woman's health company, so we never tax the adoption of our technology. So what we do is, you know, we call it a good, better, best pricing strategy. You know, we'll price, you know, our products at the base without sacrificing, you know, any pricing from the others so that people don't have, you know, to pay more for our products. And then, you know, a product like ergonomics, it's more patient driven. You know, I want the softness. Speaker 3: I want the ergonomy, the comfort.</td><td>íŠ¹ì • ì œí’ˆ í•˜ë‚˜ì™€ ê´€ë ¨ë  ìˆ˜ëŠ” ìˆì§€ë§Œ, ê´‘ë²”ìœ„í•˜ê²Œ ì ìš©ë˜ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ê²½ìŸì‚¬ ëŒ€ë¹„ ì œí’ˆ ê°€ê²© ì±…ì •ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•˜ì‹­ë‹ˆê¹Œ?<br><br>ë°œí‘œì 3: ì €í¬ëŠ” ì—¬ì„± ê±´ê°• íšŒì‚¬ì´ê¸° ë•Œë¬¸ì— ì €í¬ ê¸°ìˆ  ë„ì…ì— ëŒ€í•´ ì„¸ê¸ˆì„ ë¶€ê³¼í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì €í¬ê°€ í•˜ëŠ” ê²ƒì€ 'ì¢‹ìŒ, ë” ì¢‹ìŒ, ìµœê³ ' ê°€ê²© ì „ëµì´ë¼ê³  ë¶€ë¥´ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ë‹¤ë¥¸ ì œí’ˆë“¤ì˜ ê°€ê²©ì„ í¬ìƒí•˜ì§€ ì•Šìœ¼ë©´ì„œ ê¸°ë³¸ ê°€ê²©ìœ¼ë¡œ ì œí’ˆì„ ì±…ì •í•˜ì—¬ ê³ ê°ë“¤ì´ ì €í¬ ì œí’ˆì— ëŒ€í•´ ë” ë§ì€ ë¹„ìš©ì„ ì§€ë¶ˆí•  í•„ìš”ê°€ ì—†ë„ë¡ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¸ì²´ê³µí•™ê³¼ ê°™ì€ ì œí’ˆì˜ ê²½ìš°, ë” í™˜ì ì¤‘ì‹¬ì ì…ë‹ˆë‹¤. ê³ ê°ë“¤ì€ ë¶€ë“œëŸ¬ì›€ì„ ì›í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì¸ì²´ê³µí•™ì  ì„¤ê³„ì™€ í¸ì•ˆí•¨ì„ ì›í•©ë‹ˆë‹¤.</td></tr>
<tr><td>So they're willing to pay, you know, for that extra amount. And then as you add more technologies, they'll come on top of that. But one of the things that we've seen is that, you know, in this market, our expectation was, you know, early on, we were gonna be selling more of the smooth silk round, which is, you know, comparable in price to the most expensive offerings of our competitors, and then ergonomics was going to come later. But so far, we've been surprised that the percentage of use of ergonomics is higher than we had expected for the first year by far. Speaker 3: In fact, it's about 60% of our sales, right now when we were expecting probably 20% to come from there. Speaker 1: Okay.</td><td>ë”°ë¼ì„œ ê³ ê°ë“¤ì€ ê·¸ ì¶”ê°€ ê¸ˆì•¡ì„ ê¸°êº¼ì´ ì§€ë¶ˆí•  ì˜í–¥ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë” ë§ì€ ê¸°ìˆ ì„ ì¶”ê°€í•˜ë©´, ê·¸ê²ƒë“¤ì´ ê·¸ ìœ„ì— ë”í•´ì§€ê²Œ ë©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ê°€ ëª©ê²©í•œ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ”, ì´ ì‹œì¥ì—ì„œ ì €í¬ì˜ ì´ˆê¸° ì˜ˆìƒì€ ê²½ìŸì‚¬ë“¤ì˜ ê°€ì¥ ë¹„ì‹¼ ì œí’ˆê³¼ ê°€ê²©ì´ ë¹„ìŠ·í•œ ìŠ¤ë¬´ìŠ¤ ì‹¤í¬ ë¼ìš´ë“œë¥¼ ë” ë§ì´ íŒë§¤í•  ê²ƒì´ê³ , ì¸ì²´ê³µí•™ ì œí’ˆì€ ë‚˜ì¤‘ì— ë‚˜ì˜¬ ê²ƒì´ë¼ê³  ìƒê°í–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì§€ê¸ˆê¹Œì§€ ì²« í•´ ì¸ì²´ê³µí•™ ì œí’ˆì˜ ì‚¬ìš© ë¹„ìœ¨ì´ ì €í¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ í›¨ì”¬ ë†’ì•„ì„œ ë†€ë¼ê³  ìˆìŠµë‹ˆë‹¤.<br><br>í™”ì 3: ì‹¤ì œë¡œ í˜„ì¬ ì €í¬ ë§¤ì¶œì˜ ì•½ 60%ë¥¼ ì°¨ì§€í•˜ê³  ìˆëŠ”ë°, ì €í¬ëŠ” ì•„ë§ˆ 20% ì •ë„ê°€ ê·¸ìª½ì—ì„œ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí–ˆì—ˆê±°ë“ ìš”.<br><br>í™”ì 1: ì•Œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I wanna get back to the numbers for a second. Last night, you talked about adjusted EBITDA positive in 2025, cash flow, breakeven in 2026. So the questions that I've received include, is that one quarter of adjusted EBITDA? Is it the full year? Speaker 1: How do we think about that? And and I and a sister question to that, gross margins were impressive, last night. How much of that is Motiva in The United States? How much of that is sustainable? Speaker 4: Yeah. So, I'll take the gross margin question first. So I think you saw a very strong increase in the fourth quarter, and I think that was a reflection, primarily of two things. Right?</td><td>ì ì‹œ ìˆ˜ì¹˜ë¡œ ëŒì•„ê°€ì„œ ì–˜ê¸°í•´ë³´ê² ìŠµë‹ˆë‹¤. ì–´ì ¯ë°¤ì— 2025ë…„ ì¡°ì • EBITDA í‘ì ì „í™˜, 2026ë…„ í˜„ê¸ˆíë¦„ ì†ìµë¶„ê¸°ì ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ì œê°€ ë°›ì€ ì§ˆë¬¸ë“¤ ì¤‘ì—ëŠ”, ê·¸ê²Œ ì¡°ì • EBITDA í•œ ë¶„ê¸°ë¥¼ ë§í•˜ëŠ” ê±´ì§€, ì•„ë‹ˆë©´ ì—°ê°„ ì „ì²´ë¥¼ ë§í•˜ëŠ” ê±´ì§€ì— ëŒ€í•œ ê²ƒì´ ìˆìŠµë‹ˆë‹¤.<br><br>**í™”ì 1**: ì´ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  ê´€ë ¨ ì§ˆë¬¸ìœ¼ë¡œ, ì–´ì ¯ë°¤ ì´ë§ˆì§„ì´ ì¸ìƒì ì´ì—ˆëŠ”ë°ìš”. ê·¸ ì¤‘ ì–¼ë§ˆë‚˜ ë§ì€ ë¶€ë¶„ì´ ë¯¸êµ­ì˜ Motivaì—ì„œ ë‚˜ì˜¨ ê²ƒì´ê³ , ì–¼ë§ˆë‚˜ ì§€ì†ê°€ëŠ¥í•œ ìˆ˜ì¤€ì¸ê°€ìš”?<br><br>**í™”ì 4**: ë„¤. ì´ë§ˆì§„ ì§ˆë¬¸ë¶€í„° ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ë§¤ìš° ê°•í•œ ì¦ê°€ë¥¼ ë³´ì…¨ì„ í…ë°, ì´ëŠ” ì£¼ë¡œ ë‘ ê°€ì§€ ìš”ì¸ì„ ë°˜ì˜í•œ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë§ì£ ?</td></tr>
<tr><td>So we closed one of our manufacturing facilities, and so the overhead of that facility essentially went away. Speaker 4: Right? And we've moved the volume into the two remaining facilities we have, and we also increased the volume of production to support The United States. And so you're having, you know, a lower fixed overhead against the higher volume of production. Right? So that's driving our gross margin naturally higher. Speaker 4: Later on top of that, the early contribution from The United States. And as we've noted, you know, the ASP increase for us in The United States is on a blended basis, you know, more than two x what we sell implants for outside The United States.</td><td>ì €í¬ëŠ” ì œì¡° ì‹œì„¤ ì¤‘ í•œ ê³³ì„ íì‡„í–ˆê³ , ê·¸ë˜ì„œ í•´ë‹¹ ì‹œì„¤ì˜ ê°„ì ‘ë¹„ê°€ ë³¸ì§ˆì ìœ¼ë¡œ ì‚¬ë¼ì¡ŒìŠµë‹ˆë‹¤. ë°œí‘œì 4: ë§ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ë¬¼ëŸ‰ì„ ë‚˜ë¨¸ì§€ ë‘ ì‹œì„¤ë¡œ ì´ì „í–ˆìœ¼ë©°, ë¯¸êµ­ì„ ì§€ì›í•˜ê¸° ìœ„í•´ ìƒì‚°ëŸ‰ë„ ëŠ˜ë ¸ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë” ë†’ì€ ìƒì‚°ëŸ‰ ëŒ€ë¹„ ê³ ì • ê°„ì ‘ë¹„ê°€ ë‚®ì•„ì§€ëŠ” íš¨ê³¼ë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë§ì£ ? ì´ê²ƒì´ ì €í¬ ë§¤ì¶œì´ì´ìµë¥ ì„ ìì—°ìŠ¤ëŸ½ê²Œ ë†’ì´ëŠ” ìš”ì¸ì…ë‹ˆë‹¤. ë°œí‘œì 4: ê·¸ ìœ„ì— ë¯¸êµ­ì—ì„œì˜ ì´ˆê¸° ê¸°ì—¬ë¶„ì´ ë”í•´ì§‘ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ì–¸ê¸‰í–ˆë“¯ì´, ë¯¸êµ­ì—ì„œì˜ ASP(í‰ê·  íŒë§¤ ê°€ê²©) ì¸ìƒì€ í˜¼í•© ê¸°ì¤€ìœ¼ë¡œ ë³¼ ë•Œ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ ì„í”Œë€íŠ¸ë¥¼ íŒë§¤í•˜ëŠ” ê°€ê²©ì˜ 2ë°° ì´ìƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And so it's a very significant increase in in realized price for us against the same cost of manufacturing. So the benefit there is quite substantial. And so we do expect gross margin. Speaker 4: You know, it it's gonna increase. We talked about two to 300 basis points of increase in 2025 alone. And so we expect by the fourth quarter, we'll be we'll be above 70% blended as a company, and it'll continue to go from there as The US becomes a bigger part of the the equation. On the EBITDA question, it is that we will cross over at a at a quarter this year and to be a into positive EBITDA.</td><td>ê·¸ë˜ì„œ ë™ì¼í•œ ì œì¡° ë¹„ìš© ëŒ€ë¹„ ì‹¤í˜„ ê°€ê²©ì´ ë§¤ìš° í¬ê²Œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ í˜œíƒì€ ìƒë‹¹íˆ í½ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ì´ì´ìµë¥ ì´ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ì•„ì‹œë‹¤ì‹œí”¼, ì¦ê°€í•  ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” 2025ë…„ì—ë§Œ 200~300 ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ ì¦ê°€ì— ëŒ€í•´ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 4ë¶„ê¸°ê¹Œì§€ëŠ” íšŒì‚¬ ì „ì²´ì ìœ¼ë¡œ 70%ë¥¼ ë„˜ì–´ì„¤ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ë¯¸êµ­ì´ ë” í° ë¹„ì¤‘ì„ ì°¨ì§€í•˜ê²Œ ë˜ë©´ì„œ ê³„ì†í•´ì„œ ìƒìŠ¹í•  ê²ƒì…ë‹ˆë‹¤. EBITDA ì§ˆë¬¸ì— ëŒ€í•´ì„œëŠ”, ì˜¬í•´ í•œ ë¶„ê¸°ì— ì „í™˜ì ì„ ë„˜ì–´ì„œì„œ EBITDA í‘ìë¡œ ëŒì•„ì„¤ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And what what drives us to that is that you in the fourth quarter, we saw a step up in our operating expenses as we have now stood up our US commercial operation. Speaker 4: But as we've noted, we have the 40 salespeople in the field. We have the back office, all the distribution. Everything has been put in place now. We'll see a little bit of increase over<br>the course of the year. We'll opportunistically add salespeople as we need to, you know, need work in places as these big markets where you need to put one or two more people into the field. Speaker 4: We will do that as the growth supports it. But the infrastructure is largely there.</td><td>ê·¸ë¦¬ê³  ì´ë¥¼ ì´ë„ëŠ” ìš”ì¸ì€ 4ë¶„ê¸°ì— ë¯¸êµ­ ìƒì—… ìš´ì˜ì„ êµ¬ì¶•í•˜ë©´ì„œ ìš´ì˜ë¹„ìš©ì´ ì¦ê°€í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, í˜„ì¬ í˜„ì¥ì— 40ëª…ì˜ ì˜ì—…ì‚¬ì›ì„ ë°°ì¹˜í–ˆìŠµë‹ˆë‹¤. ë°±ì˜¤í”¼ìŠ¤, ëª¨ë“  ìœ í†µë§ê¹Œì§€ ëª¨ë“  ê²ƒì´ ì´ì œ êµ¬ì¶•ë˜ì—ˆìŠµë‹ˆë‹¤. ì—°ì¤‘ì— ê±¸ì³ ì•½ê°„ì˜ ì¦ê°€ëŠ” ìˆì„ ê²ƒì…ë‹ˆë‹¤. í•„ìš”ì— ë”°ë¼ ê¸°íšŒì ìœ¼ë¡œ ì˜ì—…ì‚¬ì›ì„ ì¶”ê°€í•  ê²ƒì…ë‹ˆë‹¤. ì¦‰, ëŒ€í˜• ì‹œì¥ì—ì„œ í•œë‘ ëª…ì˜ ì¸ë ¥ì„ í˜„ì¥ì— ë” íˆ¬ì…í•´ì•¼ í•˜ëŠ” ê³³ì´ ìˆë‹¤ë©´ ë§ì…ë‹ˆë‹¤.<br><br>ì„±ì¥ì´ ë’·ë°›ì¹¨ë˜ëŠ” ëŒ€ë¡œ ê·¸ë ‡ê²Œ í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì¸í”„ë¼ëŠ” ëŒ€ë¶€ë¶„ êµ¬ì¶•ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And as now that, you know, is now generating increasing revenue for us, and we don't need to increase a lot more spending into that. And as as Pete described, we're still looking at additional ways to find efficiency outside The United States. We don't expect our operating expenses are really gonna change too much over the course of this year. Speaker 4: And as the revenue increases against that and the gross margin is improving with The United States, that's what pushes you towards EBITDA positive. And as you move into 2026, those trends continue, and and we start to cross over into the cash flow breakeven zone as well. Speaker 1: Okay.</td><td>ê·¸ë¦¬ê³  ì´ì œ ì´ ë¶€ë¬¸ì´ ì €í¬ì—ê²Œ ì ì  ë” ë§ì€ ìˆ˜ìµì„ ì°½ì¶œí•˜ê³  ìˆê³ , ì—¬ê¸°ì— ë” ë§ì€ ì§€ì¶œì„ ëŠ˜ë¦´ í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Peteê°€ ì„¤ëª…í•œ ë°”ì™€ ê°™ì´, ì €í¬ëŠ” ì—¬ì „íˆ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ íš¨ìœ¨ì„±ì„ ì°¾ì„ ìˆ˜ ìˆëŠ” ì¶”ê°€ì ì¸ ë°©ë²•ë“¤ì„ ëª¨ìƒ‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë™ì•ˆ ìš´ì˜ë¹„ìš©ì´ í¬ê²Œ ë³€í•  ê²ƒìœ¼ë¡œëŠ” ì˜ˆìƒí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.<br><br>í™”ì 4: ê·¸ë¦¬ê³  ì´ì— ëŒ€ë¹„í•´ ë§¤ì¶œì´ ì¦ê°€í•˜ê³  ë¯¸êµ­ì—ì„œ ë§¤ì¶œì´ì´ìµë¥ ì´ ê°œì„ ë˜ë©´ì„œ, ì´ê²ƒì´ EBITDA í‘ì ì „í™˜ì„ ì´ëŒì–´ë‚´ëŠ” ìš”ì¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  2026ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ë©´ì„œ ì´ëŸ¬í•œ ì¶”ì„¸ê°€ ì§€ì†ë˜ê³ , í˜„ê¸ˆíë¦„ ì†ìµë¶„ê¸°ì  ì˜ì—­ë„ ë„˜ì–´ì„œê¸° ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 1: ì•Œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So EBITDA positive at least for one quarter this year. Mostly, it sounds like next year, and then that you'll cross over into cash flow. Speaker 4: Yes. And so so at one point this week, we'll become an EBITDA positive company, like one quarter, in likely in the second half of the year. And then next year, we will cross over at some point to be a a cash flow positive company. Speaker 1: Excellent. What are you gonna do with your cash? What a unique question. Speaker 2: That's a good question. Yeah. It's a good question. Speaker 4: We gotta get there first. Right? Which, again, we have a lot of confidence. We will.</td><td>ë”°ë¼ì„œ ì˜¬í•´ ìµœì†Œ í•œ ë¶„ê¸° ë™ì•ˆì€ EBITDA í‘ìë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ ë‚´ë…„ì— í•´ë‹¹í•˜ëŠ” ê²ƒ ê°™ê³ , ê·¸ ì´í›„ í˜„ê¸ˆíë¦„ í‘ìë¡œ ì „í™˜ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë„¤, ë§ìŠµë‹ˆë‹¤. ì´ë²ˆ ì£¼ ì–´ëŠ ì‹œì ì—ì„œ ì €í¬ëŠ” EBITDA í‘ì ê¸°ì—…ì´ ë  ê²ƒì…ë‹ˆë‹¤. í•œ ë¶„ê¸° ë™ì•ˆ, ì•„ë§ˆë„ í•˜ë°˜ê¸°ì— ë§ì´ì£ . ê·¸ë¦¬ê³  ë‚´ë…„ì—ëŠ” ì–´ëŠ ì‹œì ì—ì„œ í˜„ê¸ˆíë¦„ í‘ì ê¸°ì—…ìœ¼ë¡œ ì „í™˜ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: í›Œë¥­í•©ë‹ˆë‹¤. í˜„ê¸ˆìœ¼ë¡œ ë¬´ì—‡ì„ í•˜ì‹¤ ê³„íšì¸ê°€ìš”? ì •ë§ ë…íŠ¹í•œ ì§ˆë¬¸ì´ë„¤ìš”.<br><br>ë°œí‘œì 2: ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ë„¤, ì¢‹ì€ ì§ˆë¬¸ì´ì—ìš”.<br><br>ë°œí‘œì 4: ë¨¼ì € ê·¸ ì§€ì ì— ë„ë‹¬í•´ì•¼ê² ì£ . ë‹¤ì‹œ ë§í•˜ì§€ë§Œ, ì €í¬ëŠ” ë°˜ë“œì‹œ ë‹¬ì„±í•  ê²ƒì´ë¼ëŠ” ê°•í•œ í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But I think as as Pete noted, I mean, this company is very much focused on efficiency and becoming self sustaining. Speaker 4: And so that is the goal right now. And, you know, we cross over to that. You know, the problem you described is one we're looking forward to having. Speaker 1: What are your thoughts on m and a? Speaker 3: I think one of the most important things is to you know, innovation pipeline is organic, is rich, and, you know, we have everything that we need there for the next few years. When you think about some of the things we've done is like, you know, we talked about, like, tucking in, you know, our latest distributor from Benelux, which was an opportunistic decision.</td><td>í•˜ì§€ë§Œ í”¼íŠ¸ê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì´ íšŒì‚¬ëŠ” íš¨ìœ¨ì„±ê³¼ ìë¦½ ë‹¬ì„±ì— ë§¤ìš° ì§‘ì¤‘í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>**í™”ì 4:** ê·¸ê²ƒì´ ë°”ë¡œ í˜„ì¬ì˜ ëª©í‘œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ê·¸ ì§€ì ì„ ë„˜ì–´ì„œê²Œ ë˜ë©´, ë§ì”€í•˜ì‹  ë¬¸ì œëŠ” ì˜¤íˆë ¤ ì €í¬ê°€ ê¸°ëŒ€í•˜ê³  ìˆëŠ” ë¬¸ì œì…ë‹ˆë‹¤.<br><br>**í™”ì 1:** M&Aì— ëŒ€í•œ ìƒê°ì€ ì–´ë– ì‹ ê°€ìš”?<br><br>**í™”ì 3:** ê°€ì¥ ì¤‘ìš”í•œ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” í˜ì‹  íŒŒì´í”„ë¼ì¸ì´ ìì²´ì ìœ¼ë¡œ í’ë¶€í•˜ë‹¤ëŠ” ì ì´ë©°, í–¥í›„ ëª‡ ë…„ê°„ í•„ìš”í•œ ëª¨ë“  ê²ƒì„ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ í•´ì˜¨ ì¼ë“¤ì„ ìƒê°í•´ë³´ë©´, ë² ë„¤ë£©ìŠ¤ ì§€ì—­ì˜ ìµœì‹  ìœ í†µì—…ì²´ë¥¼ ì¸ìˆ˜í•œ ê²ƒê³¼ ê°™ì€ ê¸°íšŒì£¼ì˜ì  ê²°ì •ì— ëŒ€í•´ ë§ì”€ë“œë¦° ë°” ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But, you know, we're not going out there looking to buy growth by incorporating, you know, other technologies. We're very focused in this world of breast aesthetics, breast reconstruction. And what we have talked about is, you know, moving into contour aesthetics with, GEM. Speaker 3: GEM is, you know, basically another vertical from our minimally invasive platform, which allows for, you know, gluteal ergonomic modeling, which is a market right now. It's about 800,000 procedures worldwide. All of them done with, you know, not the most of technology not the best of technologies, you know, you have, you know, this super high<br>reoperation rate up to a hundred percent.</td><td>í•˜ì§€ë§Œ ì €í¬ëŠ” ë‹¤ë¥¸ ê¸°ìˆ ë“¤ì„ í†µí•©í•´ì„œ ì„±ì¥ì„ ë§¤ìˆ˜í•˜ë ¤ê³  ë‚˜ì„œëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ì €í¬ëŠ” ìœ ë°© ë¯¸ìš©, ìœ ë°© ì¬ê±´ìˆ ì´ë¼ëŠ” ì´ ë¶„ì•¼ì— ë§¤ìš° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ë…¼ì˜í•´ì˜¨ ê²ƒì€ GEMì„ í†µí•´ ìœ¤ê³½ ë¯¸ìš© ë¶„ì•¼ë¡œ ì§„ì¶œí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: GEMì€ ê¸°ë³¸ì ìœ¼ë¡œ ì €í¬ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì˜ ë˜ ë‹¤ë¥¸ ìˆ˜ì§ ì˜ì—­ìœ¼ë¡œ, ë‘”ë¶€ ì¸ì²´ê³µí•™ì  ëª¨ë¸ë§ì„ ê°€ëŠ¥í•˜ê²Œ í•©ë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì•½ 80ë§Œ ê±´ì˜ ì‹œìˆ ì´ ì´ë£¨ì–´ì§€ëŠ” ì‹œì¥ì…ë‹ˆë‹¤. ì´ ëª¨ë“  ì‹œìˆ ë“¤ì´ ìµœê³ ì˜ ê¸°ìˆ ì´ ì•„ë‹Œ, ê°€ì¥ ì¢‹ì§€ ì•Šì€ ê¸°ìˆ ë“¤ë¡œ ì‹œí–‰ë˜ê³  ìˆìœ¼ë©°, ì¬ìˆ˜ìˆ ë¥ ì´ ìµœëŒ€ 100%ì— ë‹¬í•˜ëŠ” ë§¤ìš° ë†’ì€ ìˆ˜ì¤€ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>You're gonna have a mortality rate. So as a woman's health company, it's something we are focused on on fixing. Speaker 3: And eventually, I think that move from just doing breast into contour aesthetics is is going to open new possibilities. So when we get there, we'll see. Speaker 1: Okay. Now my favorite question. When we're sitting here a year from now talking,<br><br>what do you think we're gonna be talking about? Speaker 2: Oh my god. Speaker 1: No pressure. And it's being written. Speaker 2: Okay. Well, you know, I think, you know, as JJ laid out, I think there's a lot of opportunities for us to grow, especially with our innovation platform. But for us today, it's just about executing.</td><td>ì‚¬ë§ë¥ ì´ ë°œìƒí•  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì—¬ì„± ê±´ê°• íšŒì‚¬ë¡œì„œ ì´ëŠ” ìš°ë¦¬ê°€ í•´ê²°ì— ì§‘ì¤‘í•˜ê³  ìˆëŠ” ë¬¸ì œì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ê·¸ë¦¬ê³  ê²°êµ­ ìœ ë°©ì—ì„œ ìœ¤ê³½ ë¯¸ìš©ìœ¼ë¡œì˜ ì „í™˜ì€ ìƒˆë¡œìš´ ê°€ëŠ¥ì„±ì„ ì—´ì–´ì¤„ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ ì‹œì ì— ë„ë‹¬í•˜ë©´ ì§€ì¼œë³´ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì¢‹ìŠµë‹ˆë‹¤. ì´ì œ ì œê°€ ê°€ì¥ ì¢‹ì•„í•˜ëŠ” ì§ˆë¬¸ì…ë‹ˆë‹¤. 1ë…„ í›„ ì§€ê¸ˆ ì´ ìë¦¬ì—ì„œ ëŒ€í™”ë¥¼ ë‚˜ëˆ„ê³  ìˆë‹¤ë©´, ìš°ë¦¬ëŠ” ë¬´ì—‡ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆì„ ê²ƒ ê°™ìŠµë‹ˆê¹Œ?<br><br>ë°œí‘œì 2: ì˜¤ ë§™ì†Œì‚¬.<br><br>ë°œí‘œì 1: ë¶€ë‹´ ê°–ì§€ ë§ˆì„¸ìš”. ê·¸ë¦¬ê³  ì´ê±´ ê¸°ë¡ë˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ì•Œê² ìŠµë‹ˆë‹¤. ìŒ, JJê°€ ì„¤ëª…í•œ ë°”ì™€ ê°™ì´, íŠ¹íˆ ìš°ë¦¬ì˜ í˜ì‹  í”Œë«í¼ì„ í†µí•´ ì„±ì¥í•  ìˆ˜ ìˆëŠ” ë§ì€ ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì˜¤ëŠ˜ ìš°ë¦¬ì—ê²ŒëŠ” ë‹¨ìˆœíˆ ì‹¤í–‰í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And and that's a lot of around the financial and operational discipline. And I think we wanna piece together good quarters. Speaker 2: I think, you know, we wanna really build the confidence that we have the capability of delivering with pipeline. And I think people are gonna look look at that, twelve months from now, which is for me right now seems a long time away. You know, that, hey. Listen. The the company is in a different trajectory. Speaker 2: We have an opportunity. We're exploiting the market opportunity we have in The US, and I think we're going to see other platforms that we can continue to build on. Speaker 1: Terrific.</td><td>ê·¸ë¦¬ê³  ì´ëŠ” ì¬ë¬´ì  ë° ìš´ì˜ì  ê·œìœ¨ê³¼ ë§ì€ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì¢‹ì€ ë¶„ê¸°ë“¤ì„ ì—°ê²°í•´ ë‚˜ê°€ê³  ì‹¶ìŠµë‹ˆë‹¤.<br><br>í™”ì 2: ì €ëŠ” ì €í¬ê°€ íŒŒì´í”„ë¼ì¸ìœ¼ë¡œ ì„±ê³¼ë¥¼ ë‚¼ ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì´ ìˆë‹¤ëŠ” í™•ì‹ ì„ ì •ë§ë¡œ êµ¬ì¶•í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‚¬ëŒë“¤ì´ ì§€ê¸ˆë¶€í„° 12ê°œì›” í›„ë¥¼ ë°”ë¼ë³¼ ê²ƒì´ë¼ê³  ìƒê°í•˜ëŠ”ë°, ì €ì—ê²ŒëŠ” ì§€ê¸ˆ ë‹¹ì¥ ë§¤ìš° ê¸´ ì‹œê°„ì²˜ëŸ¼ ëŠê»´ì§‘ë‹ˆë‹¤. ê·¸ë•Œ ì‚¬ëŒë“¤ì´ ë§í•  ê²ƒì…ë‹ˆë‹¤. "ë“¤ì–´ë³´ì„¸ìš”. ì´ íšŒì‚¬ëŠ” ë‹¤ë¥¸ ê¶¤ë„ì— ìˆìŠµë‹ˆë‹¤."<br><br>í™”ì 2: ì €í¬ì—ê²ŒëŠ” ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë¯¸êµ­ì—ì„œ ê°€ì§€ê³  ìˆëŠ” ì‹œì¥ ê¸°íšŒë¥¼ í™œìš©í•˜ê³  ìˆìœ¼ë©°, ì €í¬ê°€ ê³„ì†í•´ì„œ êµ¬ì¶•í•  ìˆ˜ ìˆëŠ” ë‹¤ë¥¸ í”Œë«í¼ë“¤ì„ ë³´ê²Œ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>í™”ì 1: í›Œë¥­í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Well, JJ, Pete and Raj, thank you so much for coming, and I hope you have a great day. Speaker 4: Thank you. Speaker 3: Thank you, Joanne.</td><td>ìŒ, JJ, Pete, ê·¸ë¦¬ê³  Raj, ì°¸ì„í•´ ì£¼ì…”ì„œ ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. ì¢‹ì€ í•˜ë£¨ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>Speaker 4: ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>Speaker 3: ê°ì‚¬í•©ë‹ˆë‹¤, Joanne.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a summary of the key points from the earnings call in Korean:<br><br>â€¢ ì‹¤ì  í•˜ì´ë¼ì´íŠ¸:<br>- 4ë¶„ê¸° ë§¤ì¶œ 4,450ë§Œ ë‹¬ëŸ¬ (ì „ë…„ ëŒ€ë¹„ 40% ì¦ê°€)<br>- ë¯¸êµ­ ì‹œì¥ì—ì„œ 330ë§Œ ë‹¬ëŸ¬ ë§¤ì¶œ ë‹¬ì„±<br>- ì´ì´ìµë¥  68.5% (ìˆ˜ë…„ ë‚´ ìµœê³  ìˆ˜ì¤€)<br><br>â€¢ 2025ë…„ ê°€ì´ë˜ìŠ¤:<br>- ë¯¸êµ­ ì™¸ ì§€ì—­ ë§¤ì¶œ 7,000ë§Œ-7,500ë§Œ ë‹¬ëŸ¬ ì˜ˆìƒ (ì¤‘ë‹¨ìœ„ í•œìë¦¬ ì„±ì¥ë¥ )<br>- ë¯¸êµ­ ì‹œì¥ ë§¤ì¶œ 3,500ë§Œ ë‹¬ëŸ¬ ëª©í‘œ<br>- 2025ë…„ ì¤‘ ë¶„ê¸°ë³„ EBITDA í‘ìì „í™˜ ì˜ˆìƒ<br>- 2026ë…„ í˜„ê¸ˆíë¦„ ì†ìµë¶„ê¸°ì  ë‹¬ì„± ì „ë§<br><br>â€¢ ì‚¬ì—… ì „ëµ:<br>- ë¯¸êµ­ ì‹œì¥ ì§„ì¶œ ì´ˆê¸° ë‹¨ê³„ì—ì„œ ë†’ì€ ì˜ì‚¬ ìˆ˜ìš©ë„ í™•ì¸<br>- í˜„ì¬ 650ê°œ ì˜ë£Œê¸°ê´€ê³¼ ê±°ë˜ ì¤‘ì´ë©° ì¼í‰ê·  90ê±´ì˜ ì£¼ë¬¸ ì²˜ë¦¬<br>- ì œí’ˆ ì°¨ë³„í™”ì™€ ì•ˆì „ì„±ì„ í†µí•œ ê²½ìŸìš°ìœ„ í™•ë³´<br>- í–¥í›„ ìœ ë°©ì¬ê±´ìˆ  ì‹œì¥ ì§„ì¶œ ë° ìµœì†Œì¹¨ìŠµ ì‹œìˆ  í”Œë«í¼ í™•ëŒ€ ê³„íš<br><br>ì´ ë‚´ìš©ì€ íˆ¬ììë“¤ì—ê²Œ íšŒì‚¬ì˜ ì„±ì¥ì„±ê³¼ ìˆ˜ìµì„± ê°œì„  ê°€ëŠ¥ì„±ì„ ë³´ì—¬ì£¼ëŠ” ì¤‘ìš”í•œ ì •ë³´ë¥¼ ë‹´ê³  ìˆìŠµë‹ˆë‹¤.</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Question-and-Answer Session</td><td>ì§ˆì˜ì‘ë‹µ ì‹œê°„</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">I don't see any transcript provided to analyze. Please share the earnings call transcript you'd like me to summarize, and I'll provide 3-5 key bullet points in Korean focusing on:<br><br>- ì£¼ìš” ì¬ë¬´ ì§€í‘œ<br>- ê°€ì´ë˜ìŠ¤ ì—…ë°ì´íŠ¸<br>- ê²½ì˜ì§„ì˜ í†¤<br>- ì ì¬ì  ë¦¬ìŠ¤í¬ ë° ê°•ì </p>
    <hr style="margin:50px 0;">
    
</body></html>